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El estudio del espacio farmacológico es una tarea muy compleja y la utilización de la gran 
cantidad de información que contiene con el fin de desarrollar nuevos fármacos obliga a 
aplicar un gran número de técnicas y aproximaciones 
En este trabajo se han aplicado dos rutas diferentes para construir una plataforma 
computacional que permita el descubrimiento de nuevos fármacos. Por un lado se han 
desarrollado herramientas para el análisis y la simulación de las interacciones 
intermoleculares entre los fármacos y sus dianas presentes en los complejos 
tridimensionales, lo que nos permite predecir la afinidades de unión y proponer nuevas 
moléculas candidatas. 
Por otro lado, se ha introducido un cambio radical en el concepto tradicional de diseño 
asistido por ordenador al incluir la farmacología de sistemas y el análisis de múltiples 
variables del espacio químico-biológico para poder estimar perfiles polifarmacológicos, 
efectos adversos y los complejos caminos de optimización que llevan desde un posible 
candidato a un nuevo fármaco. 
 
 
 
 
 
 
 
 
 
 
  
The study of pharmacological space is indeed a complex task because its tortuous nature 
demands a large number of techniques and approximations to exploit the information that it 
contains with the aim of developing new drugs.    
For dealing with the complexities involved in the construction of a fully functional 
computational platform for drug discovery In this work we have developed several tools for: 
(1) simulation and analysis of intermolecular interactions present in three-dimensional 
complexes comprising compounds and targets; and (2) approaching systems 
pharmacology and multivariate analysis of chemico-biological space with a view to 
predicting polypharmacology binding profiles, side effects and complex optimization routes 
from promising candidates to full drugs. 
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Las interacciones entre biomoléculas (proteínas, ácidos nucleicos, lípidos, metabolitos, 
etc.) constituyen el lenguaje básico de los sistemas vivos. Numerosas enfermedades están 
relacionadas con fallos de funcionamiento (Hoshino, Chatani et al. 1999) o ausencia de 
estas interacciones (Kishnani, Steiner et al. 2006) y, por tanto, estas son de vital 
importancia. Por otro lado, su estudio permitiría la manipulación de los procesos vitales 
para tratar de remediar o incluso eliminar los efectos asociados a un determinado proceso 
patológico (Strebhardt and Ullrich 2008). 
Tradicionalmente, esta manipulación se ha llevado a cabo mediante el uso de pequeñas 
moléculas, que son capaces de interaccionar con las macromoléculas biológicas naturales. 
En los últimos 30 años, la aplicación de técnicas de bioingeniería ha permitido aumentar el 
uso de productos de naturaleza proteica, como son los anticuerpos humanizados (Adams 
and Weiner 2005), las insulinas humanas y otras hormonas de carácter peptídico (Nagle, 
Berg et al. 2003; Donati and Rappuoli 2013) y las nuevas vacunas. 
Sin embargo, las pequeñas moléculas o ligandos siguen siendo de capital importancia en 
el tratamiento actual de las enfermedades humanas y animales, y ocupan un lugar 
privilegiado en este aspecto (Hann and Keserü 2012). Su descubrimiento y posterior 
lanzamiento al mercado es una tarea ardua que requiere una gran inversión en 
investigación y posterior desarrollo en fase clínica, en promedio, 15 años y 800 millones de 
dólares por molécula en fase IV (Scannell, Blanckley et al. 2012).  
Desde principios de la década de los 90 del siglo pasado, la química combinatoria y el 
cribado de alto rendimiento han producido un número muy bajo de nuevos fármacos en 
relación con la inversión realizada. Del análisis de los fármacos aprobados desde 1950, se 
desprende que el número de éstos ha permanecido prácticamente constante año tras año, 
indicando que tanto estas tecnologías como la introducción de los compuestos 
biofarmacéuticos no han supuesto el impacto revolucionario se esperaba.(Munos 2009; 
Pammolli, Magazzini et al. 2011) 
Si bien el grueso de la inversión se debe a los requisitos necesarios para demostrar la 
seguridad y eficacia de las nuevas moléculas, como son los ensayos clínicos, la fase de 
investigación pre-clínica es responsable de estos costes añadidos, en cuanto que no 
impide que candidatos poco prometedores lleguen a fases más tardías de desarrollo, 
donde el fracaso es más costoso desde el punto de vista económico (Scannell, Blanckley 
et al. 2012).  
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El proceso moderno de búsqueda de fármacos comienza con la fase de investigación pre-
clínica donde, mediante diversas técnicas, se buscan compuestos que sean capaces de 
tener un efecto sobre una diana previamente validada por tener un impacto en un proceso 
patológico. Estos compuestos que interaccionan con una afinidad baja o media se 
denominan hits. Posteriormente, estos compuestos han de ser revalidados mediante 
experimentos adicionales confirmatorios. Una vez validados, los compuestos entran en un 
ciclo de optimización-prueba donde se busca conseguir compuestos con mayor afinidad 
mediante la adición de nuevos grupos químicos a la molécula original. El resultado de este 
proceso se conoce como lead o cabeza de serie. Finalmente, este cabeza de serie entra 
en nuevos ciclos de optimización donde se busca mejorar su perfil farmacocinético y 
farmacodinámico, alterando sus propiedades fisicoquímicas y su selectividad por la diana 
en cuestión frente a otras dianas similares. Finalmente y durante todo el proceso, se 
realizan pruebas toxicológicas y de seguridad en modelos in vitro o en modelos animales, 
con el fin de intentar extrapolar los resultados al cuerpo humano. 
Los métodos teóricos, correctamente entendidos y aplicados, pueden ayudar al químico 
farmacéutico a diferenciar y elegir los candidatos más prometedores de entre los miles o 
incluso millones de posibles moléculas disponibles en las quimiotecas a su alcance. Estas 
técnicas pueden no solo identificar hits, sino que también pueden ser empleadas, con 
ciertas limitaciones, en la optimización de estas moléculas para convertirlas en leads y en 
la consecución de posteriores mejoras que conducirán a los compuestos finales.   
1.1 Proceso de unión ligando-receptor 
Actualmente hay tres modelos que representan la unión proteína-ligando. El primero de 
ellos data de finales del siglo XIX y fue postulado por Emil Fischer (Fischer 1894). Se trata 
del bien conocido modelo de llave-cerradura (lock-and-key): solo la llave correcta puede 
encajar en su cerradura. Se trata de una aproximación muy rígida, ya que no se 
consideran adaptaciones mutuas entre el ligando y la diana. Una aproximación más 
flexible, conocida como modelo de acoplamiento inducido (induced fit), fue posteriormente 
propuesta por Daniel Koshland (Koshland Jr 1958). El acoplamiento inducido considera 
que la flexibilidad intrínseca de la diana se traduce en una reorganización de su centro 
activo para acomodar a los ligandos entrantes. Por último, el modelo de selección 
conformacional (conformational selection) (Ma, Kumar et al. 1999; Tsai, Kumar et al. 1999) 
postula que es el ligando el que selecciona, de entre un conjunto de conformaciones 
accesibles de la diana, la más apropiada para su unión. Una representación pictórica de 
los tres modelos se puede ver en la figura 1.1.  
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1.2 Energética de la unión ligando-receptor 
La magnitud principal que determina la unión entre un ligando y su diana es la energía libre 
de unión, que se define como la diferencia de energías libres entre la correspondiente al 
complejo ligando-diana y la de sus respectivas especies aisladas (ecuación 1.1) con las 
que se encuentra en equilibrio. 
)ln( dbinding KRTG   (1.1) 
 
siendo R la constante de los gases ideales, T la temperatura y Kd la constante de 
equilibrio.  
 
 
Figura 1.1. Representación gráfica de los tres modelos de unión más comunes. 
 
La energía libre de unión puede descomponerse a su vez en sus componentes entálpica 
(ΔHbinding) y entrópica (ΔSbinding).         
bindingbindingbinding STHG   (1.2) 
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La parte entálpica está compuesta fundamentalmente por las interacciones específicas 
que se producen entre el propio ligando y la diana y entre las moléculas de agua que están 
presentes en el medio biológico y rodean e interacciones con las dos entidades. Por otro 
lado, la parte entrópica corresponde al hecho de la pérdida de libertad conformacional que 
experimentan el ligando y la diana al formar el complejo estable junto con el aumento de 
libertad que experimentan las moléculas de disolvente que se hallaban interaccionando 
con ligando y diana. 
Los principales tipos de interacciones moleculares que se consideran fundamentales para 
entender y racionalizar la unión ligando-diana son las siguientes: interacciones de van der 
Waals (vdW), interacciones electrostáticas, enlaces de hidrógeno, interacciones con el 
disolvente, interacciones hidrofóbicas y contribuciones entrópicas. 
1.2.1 Interacciones de tipo van der Waals (vdW) 
Cuando dos moléculas se aproximan y van entrando en contacto las interacciones de vdW 
dan cuenta dos tipos de fuerzas diferentes: a) repulsión, la cual actúa a corta distancia 
debido al solapamiento o superposición de las nubes electrónicas de los átomos que se 
acercan, y b) atracción, que se da a larga distancia por la interacción entre los electrones y 
núcleos de los diferentes átomos, y se deben más a la forma (o volumen) que propiamente 
al contenido electrostático. Ambas fuerzas dependen de la distancia entre los átomos (r) 
por lo que su representación es bastante directa. El modelo más usado es el del potencial 
de Lennard-Jones, donde el término repulsivo depende de r
-12
 y el atractivo de     r
-6
. 
1.2.2 Interacciones electrostáticas 
Las interacciones electrostáticas están presentes en la mayor parte de los procesos de 
unión (interacciones carga-carga, enlaces de hidrógeno, apilamiento de nubes π o π-π  
stacking, interacciones hidrofóbicas, solvatación, etc.). La aproximación más simple es el 
modelo Coulómbico (el producto de las cargas dividido por la distancia y una función 
dieléctrica sencilla simulando el apantallamiento del disolvente).  
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Figura 1.2. Representación del modelo Coulómbico para interacciones electrostáticas entre 
átomos. En negro, interacción positivo-positivo o negativo-negativo. En rojo, interacción 
positivo-negativo o viceversa. 
1.2.3 Enlace de hidrógeno 
Se trata de una interacción muy selectiva y altamente dependiente de la orientación de sus 
constituyentes. Se establece entre un átomo de hidrógeno unido a un átomo 
electronegativo, llamado donador de enlace de hidrógeno, y otro átomo también 
electronegativo, llamado aceptor de enlace de hidrógeno. La fuerza del enlace depende de 
la posición relativa de los tres átomos implicados, es decir de las distancias y ángulos que 
haya entre ellos (Liu, Wang et al. 2008). Su papel en el reconocimiento molecular es de 
gran importancia (Connelly, Aldape et al. 1994).  
 
Figura 1.3. Enlaces de hidrógeno y su caracterización geométrica por distancia y ángulos 
donador-hidrógeno-aceptor e hidrógeno-aceptor-átomo vecino. 
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1.2.4 El efecto del disolvente 
Las interacciones en medio biológico tienen lugar en un entorno acuoso. Cuando las 
moléculas están aisladas en disolución están completamente rodeadas de moléculas de 
agua. Sin embargo, cuando se produce la unión ligando-diana muchas de estas moléculas 
de agua son desplazadas. Este desplazamiento conlleva un gasto energético que debe ser 
contrarrestado por las nuevas interacciones formadas. Además, se produce una ganancia 
de entropía en las moléculas de agua liberadas. Desde un punto de vista teórico, hay dos 
modelos extremos para tener en cuenta los efectos del disolvente: a) modelos de 
disolvente explícito, donde las moléculas de agua están explícitamente representadas a 
detalle atómico, y b) modelos de disolvente implícito, donde se construye una función 
matemática que trata de simular el comportamiento global del disolvente. También es 
posible considerar modelos mixtos en los cuales se tienen en cuenta explícitamente 
determinadas moléculas y el resto se consideran de manera implícita.  
1.2.5 Interacciones hidrófobas 
Determinados constituyentes de las dianas, como son las cadenas laterales de algunos  
aminoácidos (leucina, valina, prolina…) al igual que muchos ligandos están formados por 
grupos o estructuras químicas de naturaleza apolar, que interactúan de manera muy pobre 
o desfavorable con moléculas polares como el agua en el que están inmersas. En el 
evento de la unión, si dos superficies hidrófobas interaccionan, dan lugar a una liberación 
de las moléculas de agua de ambas superficies, lo que contribuye a incrementar la 
entropía del sistema favoreciendo la unión. 
 
Figura 1.4. Simulación con disolvente explícito. El ligando apolar (C, verde; H, blanco), se 
encuentra en un entorno desfavorable de moléculas de agua (O, rojo; H, blanco). 
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1.2.6 Contribución entrópica 
La formación de un complejo diana-ligando lleva asociada una pérdida de libertad de 
movimiento por parte de ambas entidades que se traduce en una disminución de la 
entropía. Aparte de la entropía del disolvente (que incrementa al liberarse del ligando y la 
cavidad de la diana), la entropía del soluto (o entropía configuracional) se suele dividir en 
dos partes: conformacional y vibracional. La parte conformacional tiene que ver con la 
reducción del número de pozos de energía que tanto el ligando como la proteína pueden 
visitar una vez que ha sucedido la unión, mientras que la parte vibracional se refiere a los 
movimientos dentro de un pozo de energía en particular. La estimación de la entropía es 
muy compleja, y los márgenes de error suelen ser sensiblemente más altos que los de 
otros términos (Hou, Wang et al. 2010). 
1.2.7 Otras interacciones 
Existen otras interacciones que pueden ser tratadas de manera explícita según el modelo 
utilizado. Estas pueden incluir enlaces de hidrógeno no convencionales (-CH
… 
aceptor), 
enlaces con halógenos (Politzer, Murray et al. 2010), etc., los cuales pueden también ser 
contemplados implícitamente en el resto de términos tratados con anterioridad.  
1.3 Farmacología de sistemas 
Esta disciplina ha emergido como consecuencia de la aplicación de los principios de la 
biología de sistemas al campo de la farmacología (Zhao and Iyengar 2012). Se 
fundamenta en la aplicación de aproximaciones teóricas, como el análisis de redes a 
múltiples escalas de organización biológica (Berger and Iyengar 2009) (Figura 1.5), y 
experimentales, como son los datos disponibles de genómica y proteómica en las grandes 
bases de datos, para dar una visión global de la acción de los principios activos en un 
contexto general que incluye desde unas pocas vías de señalización a todo un genoma 
(Arrell and Terzic 2010). 
La farmacología de sistemas ha facilitado el desarrollo del concepto drug repurposing o 
reutilización de principios activos ya conocidos (Oprea, Bauman et al. 2012). También ha 
permitido avanzar en el estudio de las reacciones adversas de medicamentos, al 
considerar en su conjunto la red de posibles dianas que existen en el organismo y que 
pueden interaccionar con una molécula dada (Lounkine, Keiser et al. 2012). 
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Figura 1.5. Red compleja que resulta de analizar un conjunto de interacciones 
farmacológicas 
1.4 El espacio químico-biológico (Chemical-Biological Space, 
CBS) 
Los principios activos y las dianas sobre las que actúan conforman un espacio en el que su 
relación (afinidad) y sus propiedades fisicoquímicas (grupos químicos, polaridad, masa, 
permeabilidad a barreras biológicas, etc.) son las principales variables que lo definen.  
Este espacio químico (por parte de los ligandos o principios activos) y biológico (dianas en 
el paciente) se explora continuamente en el proceso de desarrollo de fármacos mediante la 
síntesis o descubrimiento de nuevas moléculas y su evaluación biológica posterior sobre la 
diana correspondiente. Sin embargo, la gran complejidad del CBS hace muy difícil la 
optimización de compuestos, por hoy día sigue siendo un proceso costoso y dirigido 
mediante técnicas de ensayo-error (Scannell, Blanckley et al. 2012).  
Su exploración sistemática bajo un marco bien definido de variables es lo que se conoce 
como el AtlasCBS (Abad-Zapatero, Perisic et al. 2010), en el que determinados 
subespacios del CBS (dianas, tipos de compuestos, etc.) son agrupados y mostrados en 
planos, los cuales permiten una rápida evaluación de sus propiedades químicas y 
biológicas. 
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2.1 Classical molecular mechanics 
Biological systems of interest usually are made up of millions of atoms, and even focusing 
on small parts the number of particles to deal with exceeds the tens of thousands. In fact, 
despite the continued growth in computational power, molecular modellers still have to rely 
on convenient approximations reducing the complexity of the systems under study (Barril 
and Luque 2012). In this context, the key components of the atoms are decoupled and 
simplified. According to the Born-Oppenheimer approximation (Born and Oppenheimer 
1927), the electrons move faster than the core of nuclei, as a consequence of their reduced 
mass. Therefore, from the point of view of the electrons, the nuclei are in fact frozen, and 
from the point of view of the nucleus, the electrons act like a cloud that responds 
immediately to a change in the coordinates of the core. Relaying on the difference in 
masses it looks reasonable to decouple both components and to describe the atoms as 
spheres neglecting the need to consider the electrons and their complex interactions 
explicitly.  
The downside of this approximation is that the vast majority of the interesting problems at 
the molecular level appear as a result of the behaviour and interactions of the electrons. 
For this reason extra terms and tricks have to be included in order to reproduce these 
effects to some extent at least.  
2.1.1 Force Fields 
The forces generated due to the interactions among atoms can be estimated through an 
empirical potential function based on a group of parameters from ab initio calculations, 
experimental results or a combination of both. This combination of potential and 
parameters is known as the force field. Several force fields have been developed since the 
70s (Mayo, Olafson et al. 1990; Cornell, Cieplak et al. 1995; Halgren 1996) and, in general, 
they introduce the potential as a sum of the bonding and non-bonding terms. Bonding 
terms try to reproduce the effect of the covalent bonds on the geometry of the molecule 
while the non-bonding terms try to reproduce the interaction between not bonded parts of a 
molecule or between different molecules. 
Bonding interactions, although depending on the force field, include three different terms: 
the stretching, the angle and the dihedral potentials.  
The stretching potential simulates the covalent bond between two spheres allowing a 
stretching movement between them: 
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where ki is a constant that represents the strength of the atomic bond, ri the distance 
between the atomic centers and r0i the ideal distance for that bond. 
The angular restrictions imposed by the atomic orbitals are taken into account with the 
angle potential: 
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where ki is a constant that represent the flexibility of the angle, γi the actual angle between 
the three atomic centers and γ0i the ideal angle for those three atoms. 
Finally, rotation about single bonds usually give rise to several minima and maxima in the 
potential energy function. To represent this phenomenon, the harmonic model is not 
suitable and the most popular approach is to represent it by means of a Fourier series: 
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 where n is the current minimum of the potential (commonly with a maximum of 3 or 4), Vn 
the Fourier coefficients, φ the dihedral angle of the torsional and γ the phase. 
In addition, it is common to add improper dihedrals terms to correct out-of-plane deviations 
(e.g. benzene ring). 
Non-bonding term is computed over all non-bonded atom pairs (except for 1-3 atoms and 
1-4 atoms where the potential is divided by 2) and it is decomposed into two different 
terms: van der Waals (12-6 potential calculated with a equilibrium distance and a well-
depth that depends on the pair of atoms) and the electrostatic contribution according to 
Coulomb’s law. 
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where i is the pair of atoms, Ai and Bi are the force field coefficients for that pair of atoms, ri 
the distance between the atoms, q1i and q2i the charges of the atoms and ε the dielectric 
function or constant. 
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2.1.2 Energy minimization 
Using the force field potential and function minimization algorithms such as conjugate 
gradients (Hestenes and Stiefel 1952) or steepest descent (Petrova and Solov'ev 1997) it is 
possible to optimize the geometry of a molecular system to be compatible with the 
parameters of the force field and to reach a minimum of energy in the potential surface. It is 
a necessary step prior to computationally more demanding tasks such as molecular 
dynamics or docking. 
2.1.3 Molecular dynamics 
Molecular dynamics simulations start from an initial spatial configuration of the system of 
interest (a theoretical or experimental model) and new states are generated using the 
Newton’s equations of motion for certain time steps. 
Introduced for the first time at the end of the 50s (Alder and Wainwright 1959), (Alder and 
Wainwright 1959), its popularization and extensive use did not occur until the advent of the 
digital era due to its demanding computational cost. It is noteworthy that nowadays 
molecular dynamics is one of the most employed simulation tools that is performed on 
supercomputers all over the world. Furthermore some specific computation machines have 
been developed to solely perform this task (Shaw, Deneroff et al. 2007).  
Once the force field potential is defined, Newton’s equations are applied: 
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where pi, mi, ri and Fi are the linear moment, the mass, the position and the force over the 
atom i, respectively.  
A system with N atoms will presents 6N first order differential equations (3N coordinates) 
that can be solved by using the finite differences method to obtain a trajectory of each atom 
of the system. The integration time step is crucial and it is often reduced to the highest 
vibration frequency of the system, 0.5 fs. However, it is still possible to reach 2 fs if an 
algorithm to freeze the atoms responsible of these high frequency vibrations is used 
(Andersen 1983; Hess 2008). This reduced time step is several orders of magnitude 
smaller than the time scale of most interesting molecular phenomena such conformational 
changes, protein folding or ligand binding (Pande, Baker et al. 2003).  
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The most time consuming part of the simulation is the evaluation of the non-bonded terms 
and the update of the list of pairs. For this reason, the algorithms employed try to avoid the 
update of the list at each step and use non-naive algorithms that limit the candidate atoms 
to those which are inside a sphere where the potential to evaluate is not null in practice 
(van der Waals) or switch to an alternative faster algorithms at a given distance [Particle 
Mesh Ewald for long-range electrostatic interactions (Darden, York et al. 1993)]. In addition, 
with the advent of the Graphics Processors Units (GPU), massive multi-parallel calculations 
on those small devices with optimized kernels have increased the simulations lengths 
several orders of magnitude making it possible to reach the time scale of microseconds on 
a regular basis and often milliseconds (Götz, Williamson et al. 2012). 
2.2 Docking  
Given the three dimensional structure of a target of interest, we could define molecular 
docking or just docking as the search of the most suitable 3D complex of a ligand and the 
target. 
The ligand is usually able to adopt several spatial configurations (or poses) inside the 
binding pocket of the macromolecule (usually a protein). For this reason the docking 
program should be designed to explore these possibilities (search space) and to evaluate 
the goodness of these poses by taking into account the propensity of similar interactions in 
nature (scoring function).  
The docking program could be reduced to an algorithm that navigates efficiently through 
the search space composed of all possible placements of the ligand within a 3D space and 
evaluate each of these poses according to the observed experimental interactions and the 
chemical nature of the species involved in these interactions. 
Depending on the definition of the search space, the number of combinations to try could 
exceed easily the computational power that is available today. For this reason, any 
simplification of this space could be of great importance to enhance the accuracy of the 
tools and to improve the execution times. Usually, the search is restricted to a region of the 
space, the binding pocket, where the modeller estimates that the interaction is more likely 
to take place due to additional information available on the target (enzyme, catalytic 
residues, other binders, etc.). However, a full search for the whole target is still possible 
when the user has no information regarding the binding site. In this latter case  blind 
docking is performed. 
The degrees of freedom considered in the binding event also have a severe impact on the 
speed and reliability of the process. If the two entities involved in the interaction are 
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considered as two rigid bodies (rigid docking), the search space is then reduced to six 
dimensions (three for translation and three for rotation of the ligand, which is the smallest 
molecule). If we also consider internal flexibility of the ligand and/or the internal flexibility of 
the macromolecule we are talking about fully flexible or semi-flexible docking, respectively. 
2.2.1 Rigid docking 
The simplification of considering the entities to two rigid bodies has its roots in the key-and-
lock interaction paradigm (Fischer 1894). The main advantage of this procedure is the large 
reduction of the search space (six dimensions) that even allows a brute force (exhaustive) 
algorithm to be run in a few seconds. The main problem arises when the ligand 
conformation is considered. Usually, relaxed or low-energy conformations are used, but in 
some cases there are several possibilities, or in the worst case scenario, the conformation 
of the best interacting complex is in a high-energy state imposed by the target. For this 
reason, rigid docking is not very popular nowadays although it was the only docking option 
available at the beginning of the CADD field (Kuntz, Blaney et al. 1982). However, it is still 
in use to validate new tools for docking and it will be used in the work described below.   
2.2.2 Semi-flexible docking 
Small molecules, except for the simplest rigid entities, possess some degree of internal 
flexibility. This is mainly due to the fact that low rotational barriers about their torsional 
angles allow them to rotate at the typical temperatures at which binding takes place. 
According to the choice of the algorithms to simulate this behavior they can be divided into 
multi-rigid and truly flexible approaches. The former use a rigid-docking engine with 
multiple conformers generated previously according to different methods (Monte Carlo 
Simulated annealing, exhaustive enumeration, rule-based, etc.). They tend to be faster and 
very scalable since the docking is reduced to a number of rigid dockings (McGann 2012). 
Truly-flexible algorithms explore the torsional degrees of freedom of the ligand in the 
search process adding an extra complexity to the problem and to the algorithms (Morris, 
Huey et al. 2009). Thus, the main advantage of this method is that if the best ligand pose is 
not present in an appreciable percentage of the ligand conformations in solution, the 
algorithm is still able to generate it and find the proper solution at the cost of lower 
performance. 
2.2.3 Fully flexible docking 
In fully flexible docking the internal degrees of freedom of the protein are also considered. 
These approaches can be divided into two classes depending on the degree of motion that 
is being simulated. Some targets only carry out a limited rearrangement of their binding 
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pocket side chains to accommodate ligands during/after the binding event. In this case, 
exploring only those side chains known to be flexible could improve the runtimes and 
provide a proper approximation for these targets (Sherman, Day et al. 2006). In other 
cases, targets experience a large rearrangement, involving conformational changes (e.g. 
hinge movements) (Wang and Merz Jr 2010) that cannot be approximated with the limited 
flexibility of the side chains. In these cases, protein flexibility is explored prior to docking 
and generating a series of conformations, typically from molecular dynamics simulations or 
normal mode analysis (Totrov and Abagyan 2008). These conformations are then used in a 
multi rigid protein-docking fashion. 
2.3 Search algorithms 
Throughout the history of docking, several algorithms have been applied to this task and 
new ones are constantly being developed and introduced (Kuntz, Blaney et al. 1982; Chen, 
Liu et al. 2007; Morris, Huey et al. 2009; Cabrera, Klett et al. 2012). In this section only 
those that were used in our own work will be described.  
2.3.1 Discretization of the space 
As a first step in the search algorithms some of them require a discretization of the search 
space. In this process the binding pocket, or the area selected for the search, is evaluated 
according to a scoring function at certain distances in the three dimensions (usual values 
are 0.25 Å, 0.375 Å, 0.5 Å or 1.0 Å, depending on the resolution requested), generating the 
energy, potential or scoring function grids that are stored for further use. In the program 
runtime, these values are loaded into memory and used for, typically, trilineal interpolation 
to generate scoring values for those positions not located at grid points.  
These grids speed up the docking process several orders of magnitude due to the 
avoidance of full scoring function calculations at the cost of small errors in the scoring 
values. Nevertheless, it imposes an important constraint on the docking process. Since pre-
generated values are used, no flexibility is allowed for the target unless some parts of the 
macromolecule are sampled together with the ligand, increasing the computational costs. 
Some algorithms that sample in real space are also forced to discretize the rotational 
space. In this manner, the tools can generate, in advance, a set of rotation matrices to be 
applied to the ligand in a given manner (randomly, exhaustively, etc.), reducing again the 
search space to a limited number of operations that could be performed in a reasonable 
amount of time. 
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2.3.2 Exhaustive search 
It is the slowest method but the simplest to implement. The algorithm discretizes the 
translations, or takes advance of previous discretization at the grids, and performs trials 
translating the center of mass (COM) of the ligand to the designated place. Simultaneously, 
the program samples the rotational degrees of freedom (Euler angles) increasing their 
values in a fixed amount of degrees each time or using quaternions. 
Torsional flexibility could also be simulated if multiple ligands are used, repeating the 
algorithm for each input conformation and storing the results in a common pool. 
 
Algorithm 2.1. Docking Exhaustive Search 
2.3.3 Triangle search 
This algorithm was developed with the aim of reducing the search space to provide a faster 
tool without losing possible solutions. It is based on the idea that not all of the positions in 
the search space would be compatible with the chemical features of the ligand, e.g. 
hydrogen bond acceptors are expected to be near hydrogen bond donors establishing a 
hydrogen bond and not near other hydrogen bond acceptors that could result in a repulsive 
electronic interaction. In a first step, the algorithm needs to map the designated search 
space using three different probes: carbonyl (C=O), to discover spots where a hydrogen 
bond acceptor would establish a favorable interaction, amine (N-H), to find suitable for a 
hydrogen bond donor, and methane (CH4) for any other areas with a hydrophobic nature. 
Spots are filtered according to a simple scoring function and only the best non-redundant 
probes are kept as possible placement sites of the ligand chemical features. 
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After the initial analysis of the pocket, the algorithm detects polar features at the ligand and 
creates a list of triangles with all these points that fulfill a minimum edge length. The 
triangle has to be able to superimpose the ligand with three different points at the binding 
pocket, also forming a triangle with the required conditions. Each triangle of the ligand is 
superimposed onto each triangle at the binding pocket. This algorithm has the advantage of 
being faster than a traditional exhaustive search and also avoids the discretization of the 
rotations that could miss some of the solution. The main problems are: i) the strong 
dependence on the binding zone analysis that could miss an important spot and ii) it is not 
applicable when the ligand has less than three different polar features (nitrogen or oxygen 
atoms). In this latter case, an alternative algorithm is required. 
 
Algorithm 2.2. Docking Triangle Search 
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2.3.4 Monte Carlo Simulated Annealing (MCSA) 
MCSA belongs to the family of stochastic optimization algorithms (Vanderbilt and Louie 
1984). It could be applied to those cases where the exhaustive search is not possible due 
to lack of resources or time constraints.  
The algorithm generates random transformation, or a set of random values within the 
search space, i.e. a translation, a rotation and a conformer (only in the case of 
multiconformer docking to simulate ligand flexibility) used as the starting pose. Each round 
of the algorithm is limited to a maximum number of steps or to a logical condition (if this is 
met first), e.g. No new better pose in 10 trials. At the end of each round, the temperature is 
scaled down by a certain value predetermined for optimum performance. Finally, at each 
step within a cycle, parameters for the best conformation are transformed by a random 
value to generate a new pose only if the parameters are set for transformation according to 
a new random number. The pose is evaluated according to the Metropolis criterion that 
accepts all new poses with a score better than the rest of the poses in the stack and also, 
to avoid local minima traps, it accepts high energy poses with a certain probability 
depending on the temperature of the current cycle. The temperature is high at the 
beginning to better explore the space and it ends low to restrict the search at the bottom of 
the global minimum (if found).   
 
Algorithm 2.3. Monte Carlo Simulated Annealing Search 
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2.4 Optimization algorithms 
It can be argued that all the algorithms described above could also be classified as 
optimization algorithms since docking is nothing but an optimization process of a given 
scoring function. In this section, for the sake of convenience, these optimization algorithms 
only refers to those that are usually employed in the last steps of the process (local 
optimizers) while the search algorithms involve global optimizers that try to navigate 
efficiently in a vast search space.  
2.4.1 Nelder–Mead or downhill simplex method 
Also known as the amoeba method, it was first introduced by Nelder and Mead in 1965 
(Nelder and Mead 1965) and aims for optimization of function in a N-dimensional space. 
The method starts initializing N+1 different random variation over the initial pose, where N 
is the number of variables (e.g. translation vector, rotation angles or quaternions and 
torsionals). Then it ranks the new poses according to their score and selects the two worst 
of them. If the difference in energy between the best and the worst poses is less than a 
cutoff, the algorithm ends. If not, it computes the average vector of all simplex points 
excluding the worst point and performs the reflection step (multiplied by a factor α) over 
the worst pose. If the new pose energy is better than the best energy so far, the worst point 
is replaced and a new reflection, called expansion, multiplied by a larger factor (γ) is 
attempted. If successful, the new point replaces the old one; if not, the algorithm continues.  
If  the reflection failed to find a new best point, but the new pose is better than, at least, any 
of the current members of the simplex, the worst pose is replaced with the new one. If the 
point is worse than the worst so far, a contraction step is attempted and if it works, the 
new pose replaces the old one. Finally if all other steps fail, reduction is carried out by 
means of which the poses in the simplex are averaged out with the best one.  
The main advantage of this method is that unlike steepest descent or conjugate gradients it 
does not require the computation of the gradient, which can be costly or even not possible. 
On the contrary, it usually requires more scoring function evaluations than other more 
modern methods and this makes it significantly slower.  
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Figure 2.1. 2D simplex simulation. Adapted from Wang et al.(Wang and Shoup 2011) 
2.4.2 Broyden–Fletcher–Goldfarb–Shanno (BFGS) algorithm 
It is a quasi-Newton iterative algorithm for nonlinear problems (Head and Zerner 1985). It 
uses the first and the second derivatives but the latter do not need to be evaluated and 
instead they are approximated with increasing accuracy. 
The algorithm departs from the initial pose to be optimized and calculates the gradient of 
the scoring function to find the first search direction. Then, it performs a linear search in the 
opposite direction of the gradient for an appropriate step size, and moves the pose to a 
new and better point. In the following steps, the search direction is recalculated using the 
first derivative and the approximated Hessian matrix. At the end of each step, the Hessian 
matrix is updated with the information available at the current and at the last step gradients. 
This algorithm converges faster than the simplex method but it is not able to obtain good 
solutions if the initial pose is not close to the minimum (Fletcher 1980). 
2.5 Scoring functions 
Scoring functions are mathematical functions that try to approximate or simulate the 
behavior and the molecular interactions that occur between ligands and targets in the 
binding event. Most of them are also designed to be efficient to compute and evaluate and 
tend to be differentiable (or piecewise differentiable) so that they can be used with fast 
optimization algorithms.  
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According to the data used to derive the function and parameters, scoring functions are 
classified into three classical groups: force field-based functions, empirical functions and 
knowledge-based functions. 
2.5.1 Force field-based functions 
The idea behind these functions is the use of the equations and parameters derived for the 
force fields (see classical molecular mechanics section) to evaluate the goodness of the 
interaction between ligand and target atoms. Only a reduced form of the force field 
equation is used, usually the non-bonding interaction part of it plus the dihedral terms. The 
former tries to capture the effects of attraction and repulsion between atoms, whereas the 
latter describes the resulting strain energy of a ligand-target interaction in order to avoid 
those poses with unusual torsional angles and/or with a low probability to exist. 
In the case of the present work, the Generalized AMBER force field (Wang, Wolf et al. 
2004) non-bonding terms were used: 
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where N is the number of atoms of the target involved in the interaction; n the number of 
ligand atoms; Aij and Bij the van der Waals parameters defined by the force field which 
depend on the atoms types of i and j; and qi and qj the partial atomic charges of atoms i 
and j, respectively. 
These functions require the typing and evaluation of every singe atom to identify and 
assign the proper parameters in order to evaluate the function. In some cases, this 
requirement forces to perceive the molecule, i.e. to evaluate the connectivity and the 
chemical nature of the atoms involved in the interaction. The main advantages of these 
functions are that each term has a physical meaning and that their evaluation can lead to 
important information for binding pocket analysis. 
2.5.2 Empirical functions 
These functions are based on terms that try to account for different parts of the interaction 
that can be adjusted and parameterized using binding data and multiple linear regression 
analysis. These terms, are then balanced according to a training set of receptor-ligand 
complexes and tend to represent meaningful and well-known interactions such as hydrogen 
bonds, non-polar contacts or ionic bonds.  
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The ChemScore function was proposed by Eldridge and colleagues in 1997 (Eldridge, 
Murray et al. 1997) for the prediction of free energies of binding. Later, it was improved by 
Verdonk et al in their docking program GOLD (Verdonk, Cole et al. 2003) with the following 
functional form: 
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where ΔG0 is a constant, ΔGhbond, ΔGmetal, ΔGlipo,and ΔGrot the corresponding regression 
coefficients and Hrot the number of rotatable bonds in the ligand. This last term tries to 
account for the entropic penalty that the binding event imposes over the freely rotatable 
bonds by limiting their rotational freedom. The first summation runs for all the possible 
hydrogen bond pairs. It calculates a score between 0 to 1 on the basis of block functions for 
the distance and the donor-hydrogen-acceptor angle and hydrogen-acceptor-any neighbor 
atom angle. These three functions try to characterize the strength of the hydrogen bond as 
these interactions are primarily directional. The second summation runs for all the acceptor 
atoms in the ligand and all metal atoms in the binding site, and it only depends on the 
distance between them. Improved versions of this function include an angle correction for 
certain metal atoms to reproduce their spatial configuration as found in crystals. Finally, the 
last summation runs over all pairs of lipophilic atoms and only depends on the distance.  
Block functions are characterized by two parameters and have the following functional 
form: 
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where xideal is the ideal value for the parameter and xmax the maximum allowed value for the 
parameter to consider that an interaction exists. This function returns values between 0, no 
interaction at all, to 1 when the ideal values for the interaction are met. 
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Figure 2.2. Block function representation. Adapted from GOLD docking program 
documentation(Verdonk, Cole et al. 2003). 
CRScore (Cabrera, Klett et al. 2012) is a simplified version of the scoring function 
GlideScore (Friesner, Banks et al. 2004) which was derived from ChemScore and empirical 
fitting of some force field terms. It scales down the GAFF van der Waals (Evdw) and 
Coulomb terms (Eqq) by two factors and sums directly both ChemScore hydrogen bond and 
lipophilic terms. 
lipohbondqqvdw GGEEG  130.0065.0  (2.9) 
The van der Waals term rises sharply as the distance between the atoms falls below the 
equilibrium distance and becomes strongly repulsive. By scaling down this term we avoid 
the overpenalization of near-optimum solutions in which one or more some ligand atoms 
are close to one or more target atom. The Coulomb term does not rise as fast as the vdW 
term but, as it tends to dominate the interaction with strong negative or positive values, it 
also needs to be scaled down by a factor. Finally, the hydrogen bond term rewards poses 
that present optimal hydrogen bondsings interactions according to their geometry while the 
lipophilic term accounts for the desolvation of non-polar surfaces of both target and ligand. 
 
Figure 2.3. Lennard-Jones potential 
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2.5.3 Statistical potentials 
Statistical potentials are based on distributions of intermolecular distances between 
chemical features or atoms derived from large three dimensional databases, usually the 
Protein Data Bank (Berman, Westbrook et al. 2000) or the Cambridge Structural Database 
(Allen 2002). These potentials exploit the information available in crystals of ligands and/or 
ligand-target complexes and convert it into distance-dependent Hemholtz free interaction 
energies of protein-ligand atom pairs. The general functional form is: 
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where i and j are the atoms of the target and ligand, respectively; ri,j the interatomic 
distance between i and j; pmat the distance distribution for a pair of atoms and pref the 
reference state for that pair of atoms. The distance distribution can be estimated from: 
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where N(rP,L) is the number of observations of atoms at a particular distance bin and rmin 
and rmax the minimum and maximum distances to be considered, respectively. 
The reference state (Pref) differs depending on the statistical potential. Here, we show the 
reference state of the scoring functions RankScore and PoseScore (Fan, Schneidman-
Duhovny et al. 2011) implemented and used along the present work. In these functions, the 
reference state is calculated taking into account the frequency of the distances of all of the 
atoms: 
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where 
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, )( is the number of all pairs of atom types in a particular distance bin. 
To reach the final terms ',
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jimat rp , the original terms are combined with the 
uniform distribution and the reference state respectively and the parameters are adjusted 
with a training set of complexes. 
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Figure 2.4. Potential of mean force for two different atomic pairs 
2.6 Fingerprints and structural keys 
Comparing ligands in an efficient manner is a difficult task. From the 80s there exist a large 
number of 2D and 3D comparison techniques that allows a fast screening of the 
increasingly vast chemical databases in just a few seconds (Eckert and Bajorath 2007). 
These versatile methods are grouped under the generic name of fingerprints. 
Fingerprints are strings of 0s and 1s (bitstring) that encode a certain information about the 
ligand and can be processed really fast by computers due to their binary nature. The 
information encoded can be very different, from whole molecular fragments to the number 
of atoms or bonds and inter-atomic distances between functional groups.  
The basic principle of fingerprint filtering or searching is that similar molecules (according to 
the selected criteria) should share activated bits in their fingerprints. 
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Figure 2.5. Fingerprint encoding that employs a hashing function for mapping fragments of 
1 to 7 atoms in both directions. Adapted from ChemAxon’s website(2013). 
2.6.1 MACCS  
(MDL) Molecular ACCess System is a structural key of 166-bits that indicates whether a 
predefined substructure or functional group is present or not. These fragments are 
designed to perform substructure and similarity searching in common molecular databases.  
2.6.2 Group fingerprints 
This fingerprint is defined by 306 different chemical groups (O'Boyle, Banck et al.) and 
allows filtering large databases by chemical moieties such as amides, carboxylic acids or 
benzyl derivatives. 
2.6.3 Extended Connectivity Fingerprints (ECFP) 
This family of topological (2D) fingerprints is based on the Morgan algorithm (Morgan 1965) 
which was initially designed to be able to recognize whether two molecules with different 
atom order are indeed the same molecule (molecular isomorphism). 
The Morgan fingerprint assigns, in a first iteration, labels to the atoms based on their 
connectivity. In the following iterations it uses the previous labels to classify the atoms until 
each atom has a unique identifier. In ECFP this algorithm (Rogers and Hahn 2010) is 
modified to run only a certain number of iterations rather than to complete molecular 
disambiguation. Thus the intermediate labels in ECFP are the base of the fingerprint and 
not a temporal value as they were in the original implementation. 
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Figure 2.6. Numbering iteration process in ECFP. Adapted from Extended Connectivity 
Fingerprints(Rogers and Hahn 2010) 
After each iteration, the values generated are used as input for a hash function that 
produces integer values uniformly in integer space (2
32
 in 32 bits). These are the base for 
the fingerprint. The space and the numbers generated are important to avoid collisions or 
the possibility that two different structures generate the same values.  
2.7 Similarity metrics 
2.7.1 Tanimoto coefficient  
The Tanimoto coefficient (Rogers and Tanimoto 1960) is the most popular metric for 
similarity measurement using fingerprints and other techniques such as shape overlapping 
between two structures A and B. It can be defined as the coefficient between the 
intersection of A and B and the union of A and B: 
BA
BA
Tc


  
(2.13) 
It can also be expressed computationally in terms of the number of common and of all 
activated bits in two different bitstrings: 
)|(__
)&(__
baonbitscount
baonbitscount
Tc   (2.14) 
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2.7.2 Tversky index 
This measure can be seen as a generalization of the Tanimoto coefficient (Senger 2009). It 
uses two parameters α and β to balance the weight of the features of template and 
candidate, respectively: 
ABBABA
BA
Ti




 (2.15) 
where α is the coefficient for the template and β the coefficient for the candidate. 
Depending on the values for these two coefficients the Tversky index offers different 
alternatives: 
 α = β = 1. This is equivalent to the Tanimoto coefficient since: 
ABBABABA   (2.16) 
 α = β = 0.5. This is equivalent to the Dice’s coefficient which will not be used in the 
present work. 
 α = 1, β = 0. In this case, only the features of the template are taken into account 
and the filtering becomes a superstructure search where a maximum similarity of 
1.0 means that the candidate has all the features included in the template and the 
minimum of 0.0 means that no features of the template are found in the candidate. 
 α = 0, β = 1. This last case is particular useful for substructure search. As only the 
candidate features are important, the maximum values of 1.0 will be assigned to 
structures that have the template features embedded. 
2.7.3 Manhattan distance 
Some techniques to be introduced in following next sections produce a series of descriptors 
or float values to describe the molecular properties. Thus, to calculate the similarity in this 
‘property space’ it could be useful to use a metric derived from the Manhattan distance. 
Let p and q be two descriptors vectors. To calculate the distance: 
 
n
i
ii qpqpqpd ),(  (2.17) 
where n is the number of descriptors. The distance is not bound and Armstrong et al. 
(Armstrong, Morris et al. 2010) have proposed the normalized inverse metric: 
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2.7.4 Root-mean-squared deviation (RMSD) 
RMSD accounts for the average distance between the equivalent atoms in both molecules.  
 
n
i
ii ba
n
BARMSD
21
),(  (2.19) 
where A and B are the coordinates of the equivalent atoms of the two molecules and n is 
the number of atoms. 
It is usually employed in docking validation sets where the crystallographic solution is 
available and to assess the quality of both, algorithms and scoring functions. Acceptable 
values for RMSD depend on the application: for small molecular fragments it has a limit of 
1.5 Å whereas for a normal drug-like molecule the limit is 2.0 Å. The main limitation of this 
measure is that small deviations of certain parts of the molecules (e.g. rings) can increase 
dramatically this value despite the fact that the key interactions determining the spatial 
configuration of the two entities are well reproduced. Several other measures have been 
proposed such as the Generally Applicable Replacement for RMSD (GARD) (Baber, 
Thompson et al. 2009) which addresses this fundamental issue. However they are still not 
very popular and for comparison purposes RMSD is still in use. 
2.7.5 TM-score 
Comparison of protein structures in the search for similar binding sites requires a robust 
metric that overcomes the limitations of the RMSD. The TM-Score algorithm (Zhang and 
Skolnick 2004) was designed to calculate the structural similarity between two protein 
models: 
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(2.20) 
where LN is the length of the native protein, LT the length of the aligned residues, di the 
distance between the ith pair of aligned residues, and d0 a normalized scale with a value of 
0.17. Max function denotes the maximum values after spatial superposition. 
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2.8 Pharmacophores 
Pharmacophores are groups of electronic or steric features in a molecule that are required 
for binding a target or triggering its response. Most common features include hydrogen 
bond donors, hydrogen bond acceptors, positively charged groups, negatively charged 
groups, lipophilic groups and aromatic rings. The main advantage of these features is that 
they are very general in the sense that many different chemical groups can fulfill the 
requirements of the definitions, e.g. a negatively charged group may include a carboxylic 
acid as well as a tetrazole moiety. Pharmacophores can be defined by using the 
information available in ligands that are already known or derived from important spots in 
the binding site that a ligand should match.  
2.8.1 3D pharmacophores 
Traditional pharmacophores are usually defined as a group of chemical features in 
Cartesian space. The distances between specific features tend to be expressed in bins in 
order to improve the computational speed. 
 
Figure 2.7. Pharmacophoric definitions and a compound that matches them (Liu, Zhou et 
al. 2012). 
2.8.2 2D or topological pharmacophores 
These pharmacophores encode the information of the relative position between features 
using bonds and atomic connectivity instead of an absolute spatial distance. The most 
commonly used ones are the Chemical Advanced Template Search (CATS) 2D 
pharmacophoric fingerprints. CATS were introduced by Schneider et al. (Schneider, 
Neidhart et al. 1999) and define five classical pharmacophoric types (positive, negative, 
acceptor, donor and lipophilic) and up to 10 topological distances (from 1 to 10 bonds 
between the two points) expressed in terms of up to 150 different flags that can be 
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activated or not in a given molecule. These flags can be translated from present/not 
present to 1 or 0 and grouped to form a bitstring. The resulting bitstrings can be compared 
or used as templates in virtual screening.     
 
Figure 2.8. CATS SMARTS definitions. Only the first topological distance for each class is 
shown 
 
Positive_Positive1: 
[+1,+2,+3,+4,NX3H2]~[+1,+2,+3,+4,NX3H2] 
Positive_Donor1: [+1,+2,+3,+4,NX3H2]~[OX2H,NX3H1,NX3H2] 
Positive_Aceptor1: [+1,+2,+3,+4,NX3H2]~[O,N!H] 
Positive_Negative1: [+1,+2,+3,+4,NX3H2]~[-1,-2,-3,-
4,CX3O2,SX4O2H1,PX4O2H1] 
Positive_Lipophilic1: 
[+1,+2,+3,+4,NX3H2]~[Cl,Br,I,SX2C2,CX4H3$([#6]),$([C,c])
X4H2$([#6])$([#6]),$([C,c])X4H1$([#6])$([#6])$([#6]),$([
C,c])X4$([#6])$([#6])$([#6])$([#6])$([#6]),cc] 
Negative_Negative1: [-1,-2,-3,-
4,CX3O2,SX4O2H1,PX4O2H1]~[-1,-2,-3,- 
Negative_Donor1: [-1,-2,-3,-
4,CX3O2,SX4O2H1,PX4O2H1]~[OX2H,NX3H1,NX3H2] 
Negative_Aceptor1: [-1,-2,-3,-
4,CX3O2,SX4O2H1,PX4O2H1]~[O,N!H] 
Negative_Lipophilic1: [-1,-2,-3,-
4,CX3O2,SX4O2H1,PX4O2H1]~[Cl,Br,I,SX2C2,CX4H3$([#6]),$([
C,c])X4H2$([#6])$([#6]),$([C,c])X4H1$([#6])$([#6])$([#6]
),$([C,c])X4$([#6])$([#6])$([#6])$([#6])$([#6]),cc] 
Donor_Donor1: [OX2H,NX3H1,NX3H2]~[OX2H,NX3H1,NX3H2] 
Donor_Aceptor1: [OX2H,NX3H1,NX3H2]~[O,N!H] 
Donor_Lipophilic1: 
[OX2H,NX3H1,NX3H2]~[Cl,Br,I,SX2C2,CX4H3$([#6]),$([C,c])X
4H2$([#6])$([#6]),$([C,c])X4H1$([#6])$([#6])$([#6]),$([C
,c])X4$([#6])$([#6])$([#6])$([#6])$([#6]),cc] 
Aceptor_Aceptor1: [O,N!H]~[O,N!H] 
Aceptor_Lipophilic1: 
[O,N!H]~[Cl,Br,I,SX2C2,CX4H3$([#6]),$([C,c])X4H2$([#6])$
([#6]),$([C,c])X4H1$([#6])$([#6])$([#6]),$([C,c])X4$([#6
])$([#6])$([#6])$([#6])$([#6]),cc] 
Lipophilic_Lipophilic1: 
[Cl,Br,I,SX2C2,CX4H3$([#6]),$([C,c])X4H2$([#6])$([#6]),$
([C,c])X4H1$([#6])$([#6])$([#6]),$([C,c])X4$([#6])$([#6]
)$([#6])$([#6])$([#6]),cc]~[Cl,Br,I,SX2C2,CX4H3$([#6]),$
([C,c])X4H2$([#6])$([#6]),$([C,c])X4H1$([#6])$([#6])$([#
6]),$([C,c])X4$([#6])$([#6])$([#6])$([#6])$([#6]),cc] 
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2.9 Shape similarity methods 
These methods rely on the key-lock paradigm which states that targets behave as a rigid 
lock with a predefined shape that the key (ligand) must meet to be able to bind or trigger 
the biological response. Although it was shown in the Introduction that this approach is far 
from reality and oversimplified, the truth is that these methods provide a useful starting 
point in the search for new compounds if there are other previously known ligands 
available. They do not require any structural information regarding the target and tend to 
perform scaffold-hopping better than do traditional methods based on fingerprints. In this 
work two methods of this kind were used: ElectroShape and Gaussian overlap. 
2.9.1 ElectroShape 
The ElectroShape method was developed originally by Armstrong et al. in 2010 
(Armstrong, Morris et al. 2010) and it was designed as a four dimensional extension of a 
previous method called UltraShape Recognition (USR) (Ballester and Richards 2007) by 
adding the atomic partial charge as a new descriptor.  
USR encodes the shape information using the first, the second and the third moments of 
the distributions of distances from five different points around the molecule (number of 
dimensions + 1). Using the distributions of distances ensures that these values are 
invariant to translation and rotation. These points (centroids) are defined according to the 
atom positions. The first centroid is the unweighted barycentre; the second one is the 
furthest atom from the first centroid; and the third centroid is the atom furthest from the 
second centroid. The forth centroid in USR is the atom closest to the first centroid but it is 
not used in ElectroShape, which replaces this centroid using the inner product of the 
vectors defined by the first three centroids and summing the first centroid to define two 
additional points. 
To measure the similarity between molecules, the authors proposed the use of the inverse 
of the Manhattan distance normalized by the number of descriptors (15) which spans from 
0 to 1. Thus totally dissimilar molecules score 0 and identical molecules score 1. 
The advantages and limitations of this method are clear. On the one hand these distribution 
moments or descriptors can be calculated in advance and stored easily, thereby reducing 
the computational resources needed to perform virtual screening. Also it provides a 
radically different viewpoint of the molecular shape that does not require overlapping 
optimization. On the other hand, the method only provides a one-dimensional metric for 
assessing similarity and the results cannot be visualized. 
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Figure 2.9. One-dimensional molecules carbon dioxide and hydrogen cyanide. These 
molecules are very similar in terms of steric shape, but look very different when the partial 
charges are added as an extra dimension. Adapted from Armstrong et al.(Armstrong, 
Morris et al. 2010). 
2.9.2 Gaussian molecular overlap 
This method uses the Gaussian shape model (Grant, Gallardo et al. 1996) where each 
atom is approximated by a spherical Gaussian function: 
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2
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i epr
   (2.21) 
where ri is the distance from the atomic center and α is defined by: 
i
i
i


   (2.22) 
where σi is atomic radius, with κi: 
3 2

 i  (2.23) 
The Gaussian weigh (pi) is selected to be: 
3
4
 iip  (2.24) 
From parameter optimization, pi = 2.70 and λi = 1.5514, and the values of the radius of 
each atom is adapted to its size. The calculation of the Gaussian overlap between two 
different atoms can be expressed as: 
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2.9.3 Optimization algorithm 
To calculate the shape similarity for two given molecules it is first necessary to optimize the 
overlap between them. This can be achieved with a variety of optimization algorithms. In 
the implementation developed in this work the downhill simplex method and the BFGS 
algorithm were used. These implementations are based on the analytical solution of the 
equations or are calculated in a pre-defined grid in which the template ligand is embedded. 
In our applications the downhill simplex method is activated by default, as it is more 
efficient in finding the optimum overlap from any arbitrary starting position and orientation.  
2.9.4 Starting positions 
Previous to the shape optimization step, both molecules are standardized in their spatial 
positions and orientations. First, their center of mass is translated to the origin (0,0,0). 
Then, the inertia tensor is calculated and diagonalized to obtain the rotation matrix to align 
the principal axes of the ligand with the reference frame. For the ligand, other three 
different starting orientations are calculated rotating 180 degrees each axis (Rush, Grant et 
al. 2005). The combination of these four different orientations and the downhill simplex 
algorithm make it highly probable to find the optimal overlap between the two molecules. 
2.9.5 Overlap score 
To measure the overlap, the Tanimoto index is employed and defined as: 
abbbaa
ab
c
OOO
O
T

  (2.27) 
where Oab is the Gaussian overlap between molecules a and b, Oaa the self-overlap of the 
molecule a and Obb the self-overlap of molecule b.  
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To improve chemical matching, an additional score is also implemented that only takes into 
account the overlap between chemically compatible atoms (e.g. hydrogen bond acceptors). 
The addition of this last Tanimoto score defines the total overlap measure that ranges from 
0 (no similarity) to 2 (identity). 
 
Figure 2.10. Shapes of Gaussian superimposed molecules. 
 
2.10 Virtual Screening 
There exist an increasing number of computational chemical databases that include most 
of the synthetically feasible compounds ever made in the world. However, and 
unfortunately, compound records rarely contain binding information or biological evaluation 
data.  
Virtual screening is the massive application of the techniques already described (docking, 
fingerprints, shape similarity, etc.) to screen these databases with the aim of selecting 
compounds with a higher probability to bind to certain target or group of targets. These 
methods can exploit the information contained in structural targets or in known ligands. 
2.10.1 Evaluating results 
According to several reported analysis, the accuracy of virtual screening (VS) results 
appears to be extremely dependent on the target (Cross, Thompson et al. 2009; 
Armstrong, Morris et al. 2010; Cabrera, Klett et al. 2012), most probably due to the fact that 
the large number of approximations employed are not universally applicable. To evaluate 
any new VS methodology, a database should be screened for an unknown target and 
binding of the selected compounds to the intended target should be confirmed. Those 
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experimental validations are not always possible and for that reason there exist some ad-
hoc datasets built from already known true binders to several targets and some decoys, 
which have been selected to mimic the physicochemical properties of these ligands. The 
most popular dataset is the Directory of Useful Decoys (DUD) (Irwin 2008) and this has 
been used throughout the work described in this thesis. 
Several metrics can be applied to the problem of identifying active molecules from decoys 
(needles in a haystack): 
2.10.2 Receiver operating characteristic (ROC) plot 
ROC curves try to show the performance of a binary classifier. It plots 1 – specificity (or 
false positive rate) against sensitivity (or true positive rate). The area under the curve 
(AUC) is generally used as a metric for the global performance of the method. The main 
problem with the AUC is that the plot information is missed and the early recognition 
problem appears when the AUC is not able to distinguish between very good early 
recoveries and poor late recoveries since both would have the same overall AUC. 
 
Figure 2.11. Example of ROC plot for a virtual screening experiment on  
adenosylhomocysteinase. 
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2.10.3 Enrichment factor 
To solve the ROC AUCs problem the Enrichment factor at a given percentage (N%) of the 
database can be used. This metric measures the concentration of annotated ligand among 
the top N% of the virtual screening results compared with their concentration in the entire 
database. 
totaltotal
topNtopN
N
CompoundsLigands
CompundsLigands
EF
/
/ %%
%   (2.28) 
2.10.4 Boltzmann-enhanced discrimination of receiver operating 
characteristic (BEDROC) 
The Enrichment factor is able to account for early recognition. However, it is useless for the 
rest of the database after the selected percentage. To solve both problems, namely 
enrichment factor and ROC AUC, Truchon et al.(Truchon and Bayly 2007) introduced the 
concept of BEDROC, which is similar to ROC AUC but it weighs top compounds more than 
the rest, including both results in a global value. The percentage of the database to 
overweight can be modified through a simple α parameter; the larger the value the more 
top compounds are taken into account. 
 
Figure 2.12. ROC curves with their corresponding AUCs and BEDROC AUCs. Adapted 
from Truchon et al.(Truchon and Bayly 2007) 
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2.11 Ligand efficiency indices (LEIs) 
In the process of developing new molecules, there is a tendency to gain affinity for the 
target at the cost of increasing the size of the new entities. If good potency is necessary it is 
also required that the final compound has favourable physicochemical properties such as 
molecular weight, polarity and lipophilicity which ensure that the potency is retained in vivo 
when the compound is distributed through the patient’s body.      
The need to optimize several parameters at the same time together with the potency has 
led to the development of the ligand efficiency indices (Abad-Zapatero 2007) which 
normalizes the binding energy by the property to be optimized: 
Name Definition Property 
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Weight 
Table X. 
1
Polar Surface Area (calculated). 
2
Number of polar atoms (N+O). 
3
Number of non-
hydrogen atoms. 
These indices can be used as variables for 2D plots where the chemicobiological properties 
of the compounds are represented. The affinity is represented in the radial coordinate while 
the molecular weight and polarity are depicted in the angular coordinate. 
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Figure 2.13. A 2D plot of NSEI and nBEI efficiency indices. 
LEIs planes have been successfully used to track optimization pathways in retrospective 
analsysis (Blasi, Arsequell et al. 2011) where they are able to point out the most favorable 
modifications to the original compound towards a final drug candidate. In these optimization 
projects, molecules tend to be bloated with chemical features that not always contribute 
enough to the binding free energy to overcome the fact that they confer worse 
physicochemical properties and therefore a dismiss ability to act in vivo.  
In addition, a framework based on LEIs could be useful to represent the contents of the 
databases that contain both chemical (compounds) and biological (activity) records such as 
BindingDB (Liu, Lin et al. 2007) or ChEMBL (Gaulton, Bellis et al. 2012). 
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3. OBJETIVOS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
 
 
 
 
 
1. Desarrollo de una interfaz gráfica, métodos basados en ligandos y actualización de 
la plataforma de cribado actual VSDMIP. 
 
2. Desarrollo de un nuevo protocolo de cribado virtual basado en fragmentos 
moleculares para acortar los tiempos de cálculo e incrementar la diversidad 
química de los resultados. 
 
3. Actualización y mejora de la precisión y rapidez de cálculo de la herramienta 
CDOCK de cribado virtual basado en docking sobre las estructuras de las dianas 
macromoleculares. 
 
4. Desarrollo de un servidor Web (AtlasCBS) para el análisis del espacio químico-
biológico con aplicación en la optimización de compuestos (proceso hit-to-lead). 
 
5. Desarrollar una herramienta para la predicción de efectos secundarios y análisis de 
redes en polifarmacología. 
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4. TRABAJOS DE INVESTIGACIÓN 
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Background and author’s contribution 
The was initially developed at the Bioinformatics Unit, Centro de Biología Molecular 
“Severo Ochoa”, by Dr. Rubén Gil Redondo and colleagues, based on a previous 
development of a docking engine called CDOCK (Pérez and Ortiz 2001), which was written 
by Angel Ramirez Ortiz (and later improved by Dr. Gil), and several pieces of software 
developed to incorporate existing tools in a complete distributable platform, capable of 
being ported to several computational infrastructures such as the Bioinformatics Unit 
cluster, the Mare Nostrum supercomputer or the Berkeley Open Infrastructure for Network 
Computing (BOINC) distributed over standard PCs.  
From the daily use of the platform and the analysis of the results produced, we identified 
several issues that could be improved and also multiple desirable features that were 
lacking in the 1.0 version, namely: 
 Speed. The main docking engine, CDOCK, was based on a combination of 
exhaustive sampling and Monte Carlo Simulated annealing algorithms implemented 
in Fortran77. However, the optimization step following the initial sampling was 
based on a SIMPLEX downhill algorithm that is neither deterministic, which means 
that the solution to the problem could be arbitrarily missed, nor fast, which was a 
real issue for high-throughput VS.  
 Accuracy. The scoring function implemented in CDOCK was entirely based on the 
non-bonding potential of the AMBER force field. This function, despite being able to 
discriminate extremely well native poses from non-native poses, was too restrictive 
and tended to discard near-native solutions generated by the previous sampling 
steps. 
 Lack of a ligand-based methodology. The platform features were limited to filters 
based on protein structure (CDOCK, DOCK or Autodock) except for the module for 
ROCS. No filters based on physicochemical properties, such as the famous Rule-
of-five, chemical moieties or ligand similarities were implemented. 
 Lack of ease of use. The platform was based on command-line programs and 
XML configuration files that had be handled by the users themselves. 
 Flexibility. All the protocols available considered ligand flexibility but neglected the 
inherent flexibility of the protein until the very end. Moreover, ligand flexibility was 
partially addressed by pre-generating a collection of plausible conformers according 
to energetic criteria but this proved to be not enough in some cases and to produce 
distorted geometries on a regular basis. 
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The objective of this part of the thesis was to overcome these limitations and to produce a 
new version of the platform (including a new docking engine) capable of improving the 
virtual screening results. The main author of these papers developed the new 
characteristics, tested the software and wrote the initial manuscripts. 
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Article I  
 
 
VSDMIP 1.5: an automated structure-and ligand-based virtual screening 
platform with a PyMOL graphical user interface 
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Article II  
 
 
CRDOCK: an ultrafast multipurpose protein-ligand docking tool 
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Article III  
 
 
A reverse combination of structure-based and ligand-based strategies for virtual 
screening 
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Background and author’s contribution 
The problem of diversity in chemical libraries intended for VS has been present since the 
ancient times of CADD back in the 80s. This is so because these compound collections  
tend to be built with purchasability or chemical accessibility in mind and, very often, they 
are obtained from external providers who ensure that enough amount of product can be 
acquired to perform an activity confirmation test. Tailor-made libraries can be defined as 
well if enough information on the target is available, e.g. for metalloenzymes, several 
chemical moieties such as carboxylic acids or thiol groups have a higher chance to bind 
and therefore, an exclusive library of compounds possessing these characteristics may be 
constructed.  
Anyway, whatever the source of the molecules is, the amount of time needed to perform 
the VS is directly proportional to the number of molecules in the collection, and hence, a 
rational design of the library to avoid redundancy and problematic/toxic compounds is 
desirable. 
The next manuscript describes a simple methodology to compress the chemical space of 
any virtual library minimizing the loss of diversity through the use of smaller chemical 
entities. The chemical space shrinks significantly when only small fragments are 
considered and therefore these fragments may be of use to ensure diversity at an 
affordable computational cost. In addition, to obtain a complete coverage of the drugs 
chemical space, i.e. more complex molecules with more drug-like properties, we added an 
additional expansion step, which selects all molecules in the database that map directly to 
the fragments in that part of chemical space. 
The main author of the manuscript designed the protocol, wrote the first draft of the 
manuscript and implemented the necessary scripts and applications for the analyses 
except for the original docking program (CDOCK) and VSDMIP platform, since this 
methodology was developed prior to the new docking program.  
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Fig. S1. Chemical structures and PDBIDs of the ASTEX ligands for which tautomers and 
protonation state were assigned manually. 
 
 Table S1. Additional molecules (water, ions, and groups) added to the ASTEX targets. 
Target Additional molecules 
1gpk Water 2529 
1hp0 Calcium ion 328 
1ig3 Sulfate group 609 and water 631 
1jd0 Zinc ion 901 
1owe Sulfate group 302 
1p2y Heme group 430 
1q41 Water 630 
1tow Water 571 
1w1p Water 2102 
1w2g Water 2073 
1x8x Waters 648 and 869 
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Article IV  
 
 
Comparison of Ultra-fast 2D and 3D Ligand and Target Descriptors for Side 
Effect Prediction and Network Analysis in Polypharmacology 
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Background and author’s contribution 
The advent of structure-based drug discovery provided the scientific community with a very 
reliable and rational model under the paradigm of one-illness one-target one-compound. 
On the contrary, previous discovery efforts were based on whole tissues or animals for 
testing the compounds. The main advantage of the new paradigm is the simplification of 
the tests and the confidence that the pharmacological effect is a direct consequence of the 
interaction of the drug with the proposed target. However, the downside includes three 
major caveats arising from the oversimplification of the model: i) toxicity, ii) metabolism and 
iii) lack of pharmacological effect. 
The toxicity problem could be related to metabolism but, in most cases, it can be traced 
down to hitting secondary targets to which the compound was not intended to bind. The 
reduction of the model to just one target is more prone to this kind of problems since no 
other targets are taken into account in the early stages of development.  
In silico metabolism prediction is an active field of research where most of the efforts are 
centered on creating models that rely on large databases of compounds for which several 
physicochemical properties have been measured. Nevertheless, other models based on 
physical principles or chemical reactivity do exist. These models have had moderate 
success in the prediction of which compounds are more likely to be substrates for hepatic 
enzymes or to be absorbed erratically. 
Finally, sometimes compounds that do bind to a certain target, which is related to a 
pathological process, may not show any therapeutic effect. In addition, it is known that 
several drugs on the market (mostly for psychiatric disorders) have a great impact on the 
illness due to the modulation of many targets simultaneously. These effects are hardly 
considered under the one-illness one-target paradigm and are also difficult to address from 
the computational standpoint where problems exist even when only the interaction of one 
drug with one target is modelled. 
Lately a comeback of the so-called polypharmacology has surged under the new paradigm 
of systems pharmacology. In this regard, this new field tries to address the caveats of the 
current model borrowing concepts and ideas from systems biology with an emphasis on 
network-like schemes where relations amongst targets and compounds are taken into 
account during the drug discovery process.    
In the following work, we analyzed the relationships and information present in networks 
built from comparing targets and ligands, and we tried to provide a simple tool to 
investigate these relationships and to predict possible targets and side effects for a given 
compound.  
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The author of the manuscript designed and developed the tools and methodologies 
described in the following document, performed the analyses and wrote the initial version of 
the paper.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
Supplementary Information 
 
 
1. Compounds used for off target validation 
 
Compound SMILES 2D structure 
dimetholizine COCCCN1CCN(CC1)C2=CC=CC=
C2OC 
 
denopamine  
COC1=C(C=C(C=C1)CCNC[C@H](
C2=CC=C(C=C2)O)O)OC 
 
ifenprodil 
CC(C(C1=CC=C(C=C1)O)O)N2CC
C(CC2)CC3=CC=CC=C3 
 
RO-25-6981 
CC(CN1CCC(CC1)CC2=CC=CC=C
2)C(C3=CC=C(C=C3)O)O 
 
 
 
 
 
 
2. Enrichment analysis of LBVS. BEDROC analysis (α = 20, 80% weight for top 8%) 
 
Target 
3D SEA 
EF1% 
3D SEA 
BEDROC 
AUC 
3D MAX 
EF1% 
3D MAX 
BEDROC 
AUC 
2D SEA 
EF1% 
2D SEA 
BEDROC 
AUC 
ACE 6.28 0.12 12.56 0.28 14.65 0.38 
AChE 6.54 0.20 17.75 0.33 0 0.12 
ADA 4.95 0.07 9.91 0.25 17.34 0.64 
ALR2 3.92 0.23 39.2 0.63 3.93 0.17 
AmpC - - - - 0 0.01 
AR 16.64 0.34 20.48 0.63 23.04 0.46 
CDK2 2.84 0.17 28.38 0.55 12.66 0.30 
COMT 0 0.08 0 0.21 17.41 0.57 
COX1 0 0.21 37.44 0.67 12.48 0.32 
COX2 3.76 0.10 26.55 0.59 0.47 0.02 
DHFR 11.43 0.48 15.32 0.48 18.72 0.94 
EGFR 9.88 0.25 19.33 0.36 30.26 0.68 
ER_agonist 21.19 0.50 28.76 0.64 33.30 0.48 
ER_antagonist 0 0.14 17.79 0.53 0 0.48 
FGFR1 0 0.00 5.80 0.11 6.62 0.10 
FXa 3.42 0.06 3.42 0.06 4.11 0.13 
GART 17.87 0.60 15.32 0.60 0 0.02 
GPb 0 0.15 26.83 0.52 5.69 0.49 
GR 3.88 0.07 9.05 0.15 14.22 0.29 
HIVPr 0 0.00 6.45 0.11 3.23 0.18 
HIVRT 0 0.07 0 0.07 0 0.03 
HMGA 40.40 0.50 43.29 0.93 43.29 0.96 
HSP90 0 0.02 27.46 0.65 13.73 0.44 
InhA 5.73 0.16 26.37 0.47 0 0.14 
MR 18.60 0.31 24.80 0.51 24.80 0.61 
NA 4.13 0.29 14.46 0.43 19.98 0.64 
P38 0.44 0.02 9.91 0.26 0 0.03 
PARP 2.83 0.12 11.31 0.37 11.31 0.34 
PDE5 11.18 0.21 12.30 0.30 16.77 0.60 
PDGFRb 19.25 0.27 19.25 0.28 3.50 0.06 
PNP 0 0.03 0 0.04 15.80 0.86 
PPAR 1.18 0.10 2.36 0.09 9.44 0.50 
PR 14.38 0.23 25.17 0.63 28.77 0.35 
RXR 0 0.37 19.25 0.44 19.25 0.64 
SAHH 8.95 0.51 8.95 0.56 9.09 0.78 
Src 7.52 0.37 12.54 0.26 0 0.01 
Thrombin 0 0.01 7.02 0.14 0 0.07 
TK 9.22 0.43 27.67 0.40 23.05 0.58 
Trypsin 2.06 0.05 18.51 0.50 28.80 0.51 
VEGFR2 9.07 0.14 11.34 0.22 0 0.09 
Average - 0.20 - 0.39 - 0.37 
st. deviation  0.16  0.21  0.28 
 
 
3. Details on parameterization of the networks. 
 
SEA parameters based on the DrugBank database were derived following the method described 
by Hert et al. [1]; the power-law equation was fitted used the curve fitting module of 
OpenOffice.org. 
Regarding 3D receptor network, binding pocket definitions were adopted from the sc-PDB 
database where they are available as separate files.  
Triviality name measurements were calculated using the SequenceMatcher method included in 
Python’s difflib module. 
 
[1] Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK (2008). Quantifying the relationships 
among drug classes. J. Chem. Inf. Model. 48(4): 755-765. 
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Article V  
 
 
AtlasCBS: a web server to map and explore chemico-biological space 
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Background and author’s contribution 
Pharmaceutical chemistry lies at the interface between chemistry and biology. Practitioners 
should explore chemical space looking for feasible molecules that could present favorable 
physicochemical properties while ensuring that a reasonable biological activity is achieved. 
This daunting task leads to some kind of exploration of the resulting chemico-biological 
space (CBS). Usually, this process is propelled by a systematic sampling of the chemical 
space accessible to synthetic chemists and corrected rounds after rounds by the binding 
information obtained after evaluation of the new compounds. Project analyses are difficult 
due to the lack of a systematic framework that can evaluate simultaneously the chemistry 
and the biology.  
An increasing number of databases have been made available (e.g. ChEMBL, PubChem, 
BindingDB, MOAD, etc.) which contain ligand information and their target-binding profiles. 
These databases contain nothing but a large description of several CBS available in the 
literature. However, this information could not be easily represented and tends to be shown 
as data tables. 
In this article we present a new web tool to perform generic analyses of present and past 
projects. Using very simple efficiency variables (SEI, BEI, nBEI, mBEI, NSEI, NBEI and LE) 
the tool allows to map the CBS in planes of efficiency that simplify the project information 
and show a clear pathway to the most promising candidates avoiding possible pitfalls in the 
process. These planes hold the physicochemical properties of the compounds (polarity, 
weight) and the binding information for a given target (Ki, Kd, IC50). Retrospective analyses 
showed that suitable molecules tend to be located in the upper-right corner of the planes 
where good efficiency relative to the weight and also good efficiency relative to the polarity 
could be found. The tool also allows the analysis of general databases such as PDBBind, 
ChEMBL and BindingDB in an atlas-like manner and the comparison with personal project 
information and compounds.  
The main author of the manuscript designed the interface and developed the server. The 
manuscript was written collectively by all the authors.  
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Article VI  
 
 
A computational fragment-based de novo protocol based on pseudo-Murcko 
fragmentation and ligand efficiency indices 
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Background and author’s contribution 
Computational fragment-based tools are available since the early 90s. LUDI [1] was a 
pioneer in the field, implementing a tool that is still in use today and gave birth to many 
other programs based on its philosophy and methods.  
Protocols of this kind suffer from three main problems: (i) the proper prediction of binding 
energies from the putative compounds, (ii) the resulting physichochemical profiles of the 
compounds, and (iii) the synthetic accessibility of the output molecules. The first one can 
be addressed with improved scoring schemes built specifically for the detail necessary for 
the fragments. The second one was not addressed until recently and could be improved 
using certain tricks such as rule-of-five [2] filters or ligand efficiency indices. The third and 
last depends on the nature of the fragment database itself and the rules used to connect 
new fragments to an existing molecule. It implies using fragmentation rules that take into 
account possible chemical reactions to connect them, such as in RECAP [3]. 
In this chapter we describe the implementation of a growing fragment protocol with a 
modified fragmentation scheme and an approach driven with ligand efficiency in mind.  
The main author wrote the applications and scripts, and the manuscript draft in 
collaboration with the other authors. 
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Introduction 
Fragment-based drug design (FBDD) is a mature and well established approach for drug 
discovery and optimization [4]. However, several limitations still exist related to the 
equipment and the expensive materials that are needed for the implementation of the 
protocols. For this reason chemoinformatics and computational tools can assist in 
parallel or in an independent manner to those discovery efforts by simplifying the 
fragment space to be explored or by pointing out which are the best spots within this 
space [5]. 
Although the definition of molecular fragment varies across the literature and 
depends on its intended use, the most common one takes into account size and 
physicochemical properties. This is the case of The Rule of Three definition [6], which 
states that the most successful fragments have a molecular weight of less than 300 kDa, 
a cLogP equal or less than 3 and a number of hydrogen bond donor and acceptor atoms 
of less than or equal to 3. This definition has been applied widely, but it should not be 
considered in absolute terms as some successful studies have employed fragments that 
do not fulfill one or even two of these recommendations [7]. 
Use of molecular fragments has some advantages from both experimental and 
computational standpoints. The number of fragments that can possibly exist is 
considerably lower than that of molecules with drug-like properties and fragments are 
smaller in size than most molecules in chemical libraries. In other words, fragment 
space is smaller that drug-like space and therefore it can be explored in a more detailed 
way while covering a larger diversity in the same amount of time. In some respects this 
can be viewed as if fragments compress the space described by drug-like molecules. 
However, as the size of a compound decreases its expected binding affinity towards a 
given target also decreases so that highly sensitive experimental techniques are then 
needed to detect such a weak binding event [5]. Even for computational techniques 
fragments challenge current algorithms and scoring functions, as these have been 
trained for use with drug-like molecules and are therefore unable to correctly determine 
interactions at the binding site or properly predict an accurate binding affinity value for 
a small fragment. For this reason, both the source of the fragments to be used and their 
physicochemical properties are of utmost importance for a protocol to be successfully 
used in silico on a given target [8]. 
Fragment databases are very diverse although they are commonly obtained from 
multiple suppliers which usually provide synthetically accessible small molecules or the 
result of filtering chemical libraries using the above mentioned rule of three. Another, 
and perhaps more interesting, alternative is to fragment the molecules present in drug-
like databases into smaller pieces following a rational fragmentation scheme. One such 
popular and simple procedure was designed for drug analysis and classification of 
marketed compounds [9] whereas that known as RECAP (Retrosynthetic Combinatorial 
Analysis Procedure) was designed to address the issue of availability of high quality 
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building blocks for combinatorial chemistry [3]. The former method classifies 
molecular structures according to rings (cyclic fragments that form the base of the 
molecule), linkers (the acyclic parts that link the rings) and side chains (chemical groups 
attached to the rings) whereas the latter uses specific rules to disconnect certain parts of 
the molecules according to a list of simple chemical reactions that could yield the 
original compound. Accordingly, none of these methods was developed with a view to 
docking the resulting fragments into a protein target and evaluate their possible 
affinities computationally. 
Fragment optimization methods need a yardstick to select the appropriate 
fragment each time and to warranty that the pathway chosen can be followed with no 
trouble. The most common parameter used it the ligand efficiency. Ligand efficiency 
indices (LEI) were introduced to normalize the binding free energy of compounds with 
different properties such as size, molecular weight, number of heavy atoms, etc. LEI 
[10] have demonstrated to be very effective in FBDD in both experimental and 
computational protocols [11] and have also been shown to properly describe the 
chemico-biological space (CBS) that is being used in fragment optimization [12]. 
Prospective and retrospective analyses [13; 14] have shown that a given path of 
optimization in CBS can be successfully predicted and followed using a LEIs 
framework and 2D planes. 
In the following we describe a fully LEI-driven computational protocol that 
employs a succinct and diverse database of fragments and a growing scheme to suggest 
new target-oriented compounds with drug-like properties. The protocol encompasses a 
group of tools to perform binding site analysis, docking, scoring and LEI calculations. 
A Graphical User Interface (GUI) and some scripts were developed to ease its use and 
tested with two examples available from literature. In both cases, protein kinase B and 
thrombin, the protocol was able to identify the main features responsible for the binding 
of inhibitors and guided the process towards the more active molecules as found in the 
original studies. 
 
Methods 
Protein and ligand setup 
Three-dimensional structures for proteins and ligands were prepared according to our 
standard reported protocol [15]. Briefly, proteins were extracted from Protein Data 
Bank entries upon removal of all other molecules in the file, assigned protonation states 
to all titratable residues and added hydrogen atoms and atomic charges using PDB2PQR 
[16] in accordance with the AMBER force-field [17]. Ligand protonation states were 
ascribed using OpenBabel [18] and molecules were stores as separate files. Fragments 
were built from SMILES strings using CORINA as the 3D molecular structure 
generator and stored in PDB file format as input for the protocol. 
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Fragmentation scheme 
Our fragmentation scheme follows Murcko’s [9] criteria and classifies any given 
molecular structure into three different entities: rings, linkers and side chains. However, 
we give to side chains the same relevance as to rings, considering both when generating 
fragments. Only linker-ring bonds are broken when fragments are being generated.   
Two fragment databases were built, the first one starting from eMolecules [19] 
and using the modified Murcko’s approach, which yielded 711,155 non-redundant 
fragments, and the second one, by defining a comprehensive number of common rings 
and attaching different substituents (chlorine, fluorine, methyl groups, acyclic linkers, 
amines, etc.) to the cyclic frameworks, in particular to those which are the most frequent 
ones found in the original work by Murcko et al. [9]. 
General overview 
The protocol presented here is aimed at the design of drug-like molecules using a 
structure-based approach. It starts from a defined base fragment, uses an incremental 
construction algorithm and a scoring function to prioritize the most promising solutions, 
and is guided by the optimization of the LEI known as binding efficiency index (BEI) 
and surface efficiency index (SEI) for each candidate as a way to navigate the CBS 
efficiently [20]. 
To accomplish these tasks we developed a four-module program that allows the 
user to design new compounds starting from a desired scaffold. These modules perform 
the following jobs: (1) binding pocket analysis, to provide structural and energetic 
properties needed in subsequent steps; (2) base fragment placement according to the 
information retrieved from (1); (3) sampling, by adding new fragments to the base 
fragment using a growing algorithm; and (4) scoring, to evaluate the candidates using a 
scoring function that maximizes the square sum of BEI and SEI. 
Binding pocket analysis 
Our in-house binding pocket analysis tool (cGRILL), which is formally equivalent to 
Goodford’s program GRID [21], evaluates selected cavities searching for affinity 
hotspots that are thought to contribute significantly to the binding free energy of 
putative small molecules.  
The program reads in files in PQR or PDB format containing atomic coordinates 
and partial charges for each atom, which is characterized according to its connectivity 
(bond order), ring state, chemical type and non-bonded parameters using the 
Generalized AMBER Force Field (GAFF) [22]. Next, using a user-definable definition 
and resolution (spacing) of the search space, a cubic grid is built. At each grid point 
cGRILL evaluates the interaction energy between the whole receptor and five different 
probes combining van der Waals (Lennard-Jones potential), electrostatic (Coulombic) 
and hydrogen bonding [23] (geometry-based) interaction terms. These probes are 
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thought to summarize the main stereo-electronic properties of the binding pocket and 
are defined as follows: lipophilic (CH3), hydrogen bond donor (H4N
+
) and hydrogen 
bond acceptor (=O), mixed hydrogen bond donor-acceptor (-OH), and hydrophobic. 
cGRILL implements the extended atom concept to simplify the probes and to improve 
the sampling speed over the target’s surface [21]. 
The probes are reduced to their central atom with its partial charge increased 
depending on the atoms attached to it. Accordingly, the hydrogen bond acceptor probe 
has an assigned charge of -0.37e to better represents the partial negative potential on the 
oxygen atom when it is in a carbonyl group. On the contrary, the lipophilic C atom 
probe is neutral (charge 0e) and therefore only van der Waals interactions are calculated 
for it. The functions for hydrogen bond donor, acceptor and mixed donor-acceptor 
probes include an extra term (besides van der Waals and electrostatics) that accounts for 
the geometry of the hydrogen bond and depends on: (1) the distance between the 
acceptor and hydrogen atoms, (2) the angle between the donor, hydrogen and acceptor 
atoms, and (3) the relative orientation of the planes where the atomic orbitals of the 
acceptor and the hydrogen atoms are located. The hydrophobic probe is built on the 
lipophilic one but as an extra feature it adds the inverse of the default hydrogen bonding 
term. Thus, this probe will identify those regions where the interaction between the 
receptor and water molecules is unfavorable and the binding of a small molecule (or 
fragment) will improve by the displacement of any water molecules due to the 
hydrophobic effect [24]. 
After the mapping of the binding pocket is complete, the program filters out all 
those grid points with scores higher than a user-defined cutoff value (the interaction 
energy, by definition, is negative) for each probe, which is set by default to -12.0, -4.5, -
7.0 and -1.7 kcal/mol for H4N
+
, =O, –OH, and hydrophobic probes, respectively. At 
each of the surviving points the probes compete according to their interaction energy 
values, and the best of the set becomes the representative probe at this grid point with its 
associated energy value. These grid points are then clustered and the local minima thus 
obtained are considered as hotspots and saved for further use. At each grid the 
clustering algorithm checks for the energy values of the nearest surviving points (within 
2.0Å of distance) and if at least one of these points has a better value than its own the 
grid point is discarded [25].  
 
Base fragment placement 
The next step entails the selection of a starting or “base fragment” and its positioning 
within the binding pocket. This fragment typically comes either from an experimentally 
screened library coupled to crystallographic data to characterize its binding mode or 
from a previous virtual screening campaign. 
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An experimentally confirmed fragment hit at the starting location is not 
necessary but it increases the odds of a successful final design. Besides, and depending 
on the structure-activity landscape of the target, it is possible that the resulting 
optimized compounds will not share the binding mode of the starting fragment [26]. 
This risk can be minimized by using feature-rich fragments that establish relatively 
strong and defined interactions with the target. Computational starting points are also 
possible. However, docking-based poses are prone to very well-known errors [27] and 
do not always ensure that the final molecule will interact with the target as predicted. In 
the proof-of-concept applications presented here our methodology uses base fragments 
with experimentally determined binding modes. 
Sampling and growing 
This is the iterative process by means of which fragments from different databases are 
tried out (see below) and added to the base fragment. After each step a simplex method 
for energy minimization [28] can be used to refine the pose. 
The growing algorithm employs four databases of putative fragments that are 
meant to match the four different types of hotspots detected by the binding pocket 
analysis tool, i.e. hydrogen bond donor, hydrogen bond acceptor, mixed hydrogen bond 
donor-acceptor and hydrophobic. 
Sampling is a completely interactive step and starts with the user selecting an 
atom of the base fragment and a destination hotspot. Then, the program chooses the 
appropriate database of fragments depending on the type of hotspot and makes up 
candidate molecules by appending each fragment to the base fragment using hydrogen 
atoms from the former and the selected atom from the latter. Bond lengths are assigned 
according to the nature of the atoms being bonded. The SIMPLEX algorithm is then 
applied to fine-tune the pose at the binding pocket by optimizing: (1) the six rigid body 
degrees of freedom (translations and rotations) of the ligand, (2) the ligand rotatable 
bonds, and (3) the hydrogen bond donor groups of the target. Whether the base 
fragment remains frozen or it is allowed to move during this process is up to the user. 
Scoring 
We have implemented three different scoring functions that perform distinctly 
depending on the properties of ligand or fragment and the binding site: (1) MM-ISMSA 
[29], of general use; (2) ChemScore [30], better suited for non-charged ligands and 
hydrophobic pockets; and (3) HYDE [31], which works best for accurately placed 
ligands and could be applied to any protein–ligand (fragment) structure. The three 
scoring functions have been described extensively and tested against a wide range of 
targets [29; 32; 33] and scoring/ranking problems. This means that their relative 
strengths and weaknesses regarding binding pockets and ligands (fragments) are well 
known. 
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MM-ISMSA is an ultrafast and accurate force field-based scoring function that 
includes (1) a molecular mechanics (MM) part based on a 12−6 Lennard-Jones 
potential; (2) an electrostatic component based on an implicit solvent model (ISM) [34] 
with individual desolvation penalties for each partner in the protein−ligand (fragment) 
complex; and (3) a surface area (SA) contribution to account for the loss of water 
contacts upon protein−ligand (fragment) complex formation. As force field-based 
scoring functions are known to be well suited for pose prediction in docking and to 
discriminate efficiently amongst native and non-native candidates [35], MM-ISMSA is 
the default scoring function for sampling and final evaluation in our protocol. 
The empirical function ChemScore decomposes the binding energy in terms of 
(1) a lipophilic contribution (only for non-polar atoms), (2) hydrogen bonding 
interactions (with a geometry-dependent function), (3) metal interactions (when present 
and only for hydrogen bond acceptor atoms), and (4) an entropic penalty for the 
freezing of rotatable bonds during the binding event (proportional to the number of 
rotatable bonds). In our implementation, this function lacks any penalty terms for high 
energy conformations or very tight binding molecules (atomic clashes). Therefore it will 
perform optimally in the evaluation of final poses that are force field-compliant in terms 
of both geometry and energy.  
HYDE (HYdration and DEhydration) assumes that the main contributions to the 
binding free energy arise from hydrogen bonding interactions between the target and the 
ligand (fragment) and also that the accompanying desolvation event can either favor or 
penalize binding depending on the nature of the interacting chemical groups. The 
hydrophobic/hydrophilic nature of the atoms is determined by means of logP atomic 
contributions using empirically deduced coefficients from experimental values. The free 
energy is estimated depending on the balance between the geometry of the hydrogen 
bonds and the complementarity of target and ligand (fragment) surfaces.  
To guide the growing scheme we have introduced a LEI-driven algorithm which 
calculates BEI and SEI for each candidate molecule and then plots the BEI vs. SEI 
efficiency plane [36]. To optimize both indices at the same time, the sum of their 
squared values is computed. This information will help the user to decide which of the 
best possible candidates will be selected as the base fragment for the next round of 
growing. 
 
Results 
The program 
Our in-house pocket analysis tool, cGRILL, was implemented as a standalone C 
program making use of some parts of the molecular library presented in our previous 
works [37]. It can be used in command-line mode or within the molecular visualization 
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and editing program PyMOL [38] as a graphical user interface (GUI) plugin. The GUI 
has four different tabs (Fig. 1): 1) Run cGRILL, the interface to define the search space 
at the protein and the grid spacing, the name of the protein file and two buttons to start 
and to stop the calculation; 2) Load Grids, to load the grids into the PyMOL session 
from either the current or a previously saved analysis, and to display the calculated 
affinity maps with an arbitrary at user-definable cutoff values; 3) Configuration tab, to 
inform the program where the binary of the cGRILL code is located and the working 
directory to store the results; and 4) About tab, where credits and support information 
are provided. 
Figure 1 near here 
The main protocol interface was developed as a python script that processes the 
base fragment and the specified fragment library and builds up new molecules by using 
a linker program (developed in C). This program generates all the possible 
combinations between the two entities, the base fragment and the library. Then, the 
script calls an energy minimization and sampling routine that processes the protein and 
each putative molecule. 
The last part of the protocol is driven by another script which, using the 
OpenBabel Python wrapper Pybel [39] computes the polar SA and the molecular weight 
of the candidates to calculate BEI and SEI values and the efficiency plane, being ready 
for the next step, where the user can chose its starting point. 
Example 1: Protein Kinase B (PKB) inhibitors with a 4-phenyl-1H-pyrazol scaffold 
PKB is a serine/threonine kinase that regulates many pathways in cell growth and 
differentiation. Saxty et al. published a series of compounds obtained from a fragment-
based lead discovery campaign, [40] and provided inhibitory activity values (IC50), a 
simple ligand efficiency metric and the crystal structure of each intermediate in the 
optimization process. Using all this data we applied our protocol with the aim of 
comparing in silico proposed candidates (structures and binding modes) with the 
experimental results just mentioned and their specific location on the efficiency plane. 
After their fragment screening the authors identified 5-methyl-4-phenyl-1H-
pyrazole (Fig. 2) as a hit scaffold. This small molecule was soaked into a crystal of 
PKA-PKB hybrid proteins and the binding mode was determined. Starting from this X-
ray structure (PDB id. 2UW3) we selected this moiety as the base fragment and the 
protein without the ligand was submitted to binding pocket analysis.  
Figure 2 near here 
Three different hotspot regions were identified (Fig. 3): (1) a strong hydrophobic 
cluster, located at the same place as the phenyl ring of the base fragment and two mixed 
hydrogen bond donor-acceptor hotspots which are coincident with the two nitrogen 
atoms in the pyrazole ring; (2) right at the top of (1) a mixed hydrogen bond donor-
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acceptor spot spreading along the bottom of the pocket pointing towards a cavity 
(hereafter referred as the next step in the optimization pathway); and (3) a positively 
charged cluster with a mixed hydrogen bond donor-acceptor character located near the 
DFG motif, a key element in kinases activation/inactivation processes [41]. 
Figure 3 near here 
Next, we started the growing process using cluster (3), the para position of the 
phenyl ring, because cluster (1) was already in use by the base fragment and cluster (2) 
is farther away from the initial fragment. Each possible combination of fusing 
individual fragments from the library and the base fragment was explored. Once a 
putative molecule was built, the sampler module optimized the ligand’s rotatable bonds 
while keeping the base fragment rigid and used the GAFF non-bonded terms to select 
the best pose. Finally, at the end of the first round, SEI and BEI were evaluated for all 
those compounds giving rise to a favorable binding free energy using their scores and 
plotted for visual inspection (Fig. 4). Table 1 shows the top four compounds selected 
together with their BEI and SEI associated values. 
Figure 4 near here 
Table 1 near here 
Example 2: Highly potent thrombin inhibitors  
Thrombin is a serine protease involved in the blood coagulation cascade and therefore a 
main target for anti-clotting agents. Despite the fact that many compounds have been 
developed only a few have made it into the clinic. Here we follow the optimization of a 
series of inhibitors originally published by Klebe et al. [42] and based on the structure 
of the peptide inhibitor D-Phe-Pro-Arg (Fig. 5, left). The authors explored S1 and S3 
subpockets and rationalized the activity enhancements as they went along the series 
(Fig. 5, right). 
Fig. 5 near here 
The binding pocket analysis step of our protocol started with the X-ray structure 
of thrombin (PDB id. 2ZFP) co-crystalized with 1-[(2R)-2-aminobutanoyl]-N-(3-
chlorobenzyl)-L-prolinamide, a close analog of the peptide inhibitor whose scaffold was 
used as the base fragment for further optimization attempts. cGRILL identified three 
main putative interaction areas (Fig. 6): (1) the S1 subpocket, where a cluster of three 
different hotspots was found. First, a hydrophobic one in the middle of the cavity (a ring 
would clearly contribute to the binding free energy); a positively charged hotspot at one 
end and a mixed hydrogen bond donor-acceptor region at the other end of the cavity. 
Therefore, a positively charged group in the former (para position) and a halogen atom 
in the latter (meta position, m-) would provide candidates with increased affinity; (2) the 
central part of the binding pocket, filled with four hotspots of mixed hydrogen bond 
donor-acceptor character and a positively charged region; and (3) the S3 subpocket, 
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with a single hydrophobic hotspot. Selecting the scaffold derived from the tripeptide 
(Fig. 5) as the base fragment (extracted from the previously described co-crystallized 
structure) there are two different optimization paths that can be taken: the S1 and the S3 
subpockets. Given that in both cases the hotspot nearest to the base fragment is 
hydrophobic we chose to use a ring fragment library composed of saturated and 
unsaturated rings with 3 to 6 atoms including common combinations of nitrogen, 
oxygen and sulphur atoms with usual substituents (e.g. halogens, methyl, amines). Each 
possible link between the base fragment and the additional fragments were explored at 
meta, para, and ortho positions. 
Figure 6 near here 
The results on S1 confirm that the m-chlorine aromatic rings of 5 and 6 members 
are the preferred ones and that the chlorine atom is well buried into the pocket. In 
addition, positively charged groups provide the largest increase in the binding free 
energy due to an extra interaction with residue Asp189 at the bottom of the S1 pocket. 
On the other hand, for S3 only pure hydrophobic fragments were used as there was no 
polar hotspot near the original hydrophobic core. The results show that the most 
efficient compounds are those with saturated rings of 5 to 6 carbon atoms and mono-
substituted ciclopentane rings with a bromide atom filling the lower part of the 
subpocket. SEI and BEI were then evaluated for the top compounds using their scores 
and plotted for visual inspection (Fig. 7). Table 2 shows the top compounds selected for 
S1 with their BEI and SEI values. 
Figure 7 near here 
Table 2 near here 
 
Discussion 
Our novel FBDD protocol uses (1) a database of diverse and limited number of 
fragments obtained from common synthesizable scaffolds and (2) an incremental 
growing scheme where molecular growth is driven by efficiency planes employing BEI 
and SEI. In this way we ensure that the new proposed candidates will be synthetically 
accessible and endowed with the appropriate physicochemical properties. These two 
issues are, in essence, the main differences among the many programs that have been 
developed since LUDI, the pioneer in the field, was published back in the early 1990s 
[1].  
On the one hand, the exploration of the fragments’ chemical space should be done in a 
way that properly covers the largest possible percentage of it while, at the same time, 
keeps the computational costs affordable and produces molecules that could be actually 
synthesized by chemists. Some strategies that follow on these guidelines are Fragment 
Optimized Growth [43], whose growing engine uses a Markov chain to bias the search 
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process; COLIBREE [44], which makes use of a particle swarm optimization algorithm 
and a series of linkers related to certain chemical reactions to ensure synthetic 
accessibility; RECAP [3], which follows chemically inspired rules to break molecular 
databases into fragments that may be connected to the main scaffold afterwards through 
a feasible reaction; and SQUIRRELnovo [45] a molecular superposition algorithm 
using bioisosters and Flux [46] a program that employs a stochastic algorithm and a 
ligand-based similarity score to a given template.  
On the other hand, highly scored candidates must fulfill certain physicochemical 
properties to be properly considered as hits. Most implementations rank molecules by 
relying on a fast scoring function coming from docking programs instead of using a 
more reliable function, although more expensive in computational terms, such as MM-
PBSA [47], Free Energy Perturbation (FEP) [48], or Thermodynamic Integration (TI) 
[49]. The main problem with this approach arises from the fact that key properties such 
as solubility or size are not adequately considered. Therefore, these functions tend to 
award high scores to large molecules (as a consequence of its pairwise-interaction 
nature) irrespective of the goodness of their fits. Two examples of mixing different 
approaches to guide the process of selecting  compounds are LigBuilder 2.0 [50], where 
a genetic algorithm couples a binding affinity prediction and the evaluation of 
physicochemical properties, and PhDD [51], which uses non-compliance to Lipinski’s 
rule of 5 and an excessive number of rotatable bonds as criteria to discard compounds 
with a poor profile. However, Lipinski’s rules or another drug-like set of properties may 
be too restrictive a criterion and lead to discarding some promising molecules.  
 Taking into account the successful results obtained for the two tested targets and 
bearing in mind that BEI and SEI rely on estimated force-field based interaction 
energies, the protocol developed here by coupling a growing algorithm and a LEI-
driven scheme seems to be an appropriate way to optimally navigate through the 
chemicobiological space finally yielding the most active compounds in both cases. 
However, care must be taken as the protocol not only depends on the selection and 
positioning of the base fragment but also on how accurate we describe de binding site. 
Summarizing, computational schemes as the one presented here pave the way to a more 
rational drug design paradigm based on the incremental construction of putative 
candidates. 
 
Conclusions 
A group of computational tools to perform in silico FBDD has been developed using an 
innovative approach to solve the two most important problems found in this techniques, 
namely (1) the synthetic accessibility of the new molecules by making them up from 
databases of high frequently fragments used in marketed compounds, and (2) the 
guidance of the optimization process by the simultaneous fine-tuning of two ligand 
efficiency indices (BEI and SEI). By combining these two approaches we were able to 
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find the most promising compounds in two retrospective examples using protein kinase 
B and thrombin as targets. 
 CGILL and the scripts are open source and can be downloaded free of charge 
following registration at the CBM Bioinformatics Unit’s web page 
(http://ub.cbm.uam.es/). 
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Table 1. Four top molecules resulting from the first optimization round in the search of 
PKB inhibitors: chemical structure, BEI and SEI LEIs values and some comments. 
Compound BEI SEI Comment 
 
55.2 7.2 
This compound is pointing 
towards the next step of the 
optimization pathway. 
 
53.1 7.8 
Most efficient compound found 
experimentally (IC50 = 3.0 ± 1.2 
μM, LE=0.51) 
 
55.1 7.5 
Compound Selected by the 
authors, although not the most 
efficient (IC50 = 5.2 ± 3.3 μM, 
LE=0.48) 
 
50.5 8.0 
This compound is pointing out the 
next step of the optimization 
pathway. 
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Table 2. Top molecules resulting from the first optimization round in the search of 
thrombine inhibitors: chemical structure and BEI and SEI LEIs values. 
Compound BEI SEI 
S1
1
 
 
19.4 10.7 
 
18.4 10.2 
 
19.1 10.0 
S1
2
 
 
52.1 13.7 
 
47.9 12.2 
 
38.0 11.6 
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Figure 1. cGRILL graphical user interface. 
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Figure 2.  Base fragment for the optimization process. 
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Figure 3. Binding site analysis results for the kinase PKA.  
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Figure 4. Efficiency plane for the putative kinase inhibitors  
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Figure 5. Base fragment for thrombin and the optimization pockets. 
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Figure 6. Thrombin binding site analysis results. 
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Figure 7. Efficiency planes for S1 subpocket analysis with normal (A) and positively charged 
fragments (B). 
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5. DISCUSIÓN 
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The computational study of pharmacological space is a daunting task because it entails not 
only the intermolecular interactions governing the binding process, which must be modeled 
using atomistic scales and rigorous physical theories, but also the thousands of molecular 
relationships in the biological systems where drugs work which should be modeled using 
large networks containing all the relevant information. 
In this thesis, a few research items have already been presented that, at least in part, try to 
address these topics to some extent: i) articles I, II and VI are related to low-level drug 
discovery approaches and to the introduction of these capabilities in an integrated platform 
for drug discovery and ii) articles III, IV and V introduce a more general concept where the 
high-dimensional spaces are studied and their complexity is analyzed or reduced for 
prediction of drug activities, side effects or compounds optimization.  
We started off by addressing the main issues of the drug discovery platform that existed in 
our lab at that time. The improvement in “ease of use” was accomplished by implementing 
a new graphical user interface as a plug-in for the popular molecular visualization and 
editor program PyMOL (Schrodinger). The user introduces a few parameters regarding the 
system under study and the interface re-uses this data to generate complex configuration 
files and set up execution environments for the underlying applications. In this new version 
1.5 of the VSDMIP (Cabrera, Gil-Redondo et al. 2011), a base system for ligand-based 
virtual screening was also developed where a 2D or 3D ligand similarity query could be 
executed using a cartridge developed to run inside the database. Chemical group filtering 
and obtention of fingerprints were made possible by using SMARTS patterns in the groups 
and OpenBabel MACCS files (O'Boyle, Banck et al.). The new SMARTS definitions for the 
2D pharmacophoric fingerprints called CATS (Schneider, Neidhart et al. 1999), were 
implemented and tested. The 3D pharmacophores, initially integrated in the database, were 
redesigned for scalability as a new distributable module. 
Despite these improvements, the platform still suffers from some limitations. The MySQL 
database, which is also a distinct feature that allows storing the results and pre-processed 
molecules for different protocols, currently imposes some restraints on the flexibility of the 
molecules. Degrees of freedom of small molecules are reduced to rigid-body motions and 
discrete torsional freedom. All torsionals are encoded as a string of possible dihedral 
angles corresponding to minima and the values selected for a current conformer. This 
approach clearly limits the true flexibility of the ligands, where the movements of the 
rotatable bonds could strongly influence the positions of the atoms, producing too rigid 
models that do not correspond to the poses derived experimentally. On the other hand, this 
way of saving the information reduces significantly the storage costs and accelerates VS 
protocols because ensembles of pre-generated conformers are utilized. 
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In the last 10 years, the generic workflow platforms KNIME (Berthold, Cebron et al. 2008) 
and Pipeline Pilot (Pilot) have gained ground and limited the development of custom-made 
alternatives. These platforms present some advantages that make them preferable to 
develop in-house technology: large communities of users and developers exist, strong 
companies support them, third parties develop plug-ins and configuration is easily 
accomplished through graphical interfaces. Possible future developments of VSDMIP 
should address these facts and try to use standard platforms like the open source KNIME 
as a modern base to deploy the VS protocols. 
The speed and accuracy problems in CDOCK (Pérez and Ortiz 2001) were undertaken by 
designing and implementing a new flexible docking tool called CRDOCK (Cabrera, Klett et 
al. 2012). This new program was implemented from scratch in C language as a series of 
library routines that allowed its faster development and modularization. We have licensed 
the docking program under the GNU General Public License (GPL) v2 or above to make 
the code available to the scientific community. CRDOCK improved the runtime speed by 
simplifying the search space, pre-scanning the binding pocket with three probes (hydrogen 
bond acceptor, hydrogen bond donor and lipophilic). In this manner, the compounds’ 
features are placed only where chemical complementarily could be expected. When no 
distinct features can be found in the molecules or in the binding pocket, the program relies 
on a traditional Monte Carlo Simulated Annealing algorithm or performs an exhaustive 
search. The tool is built on top of a simple library of molecular operations which is also the 
base of other tools in this thesis. The CDOCK behavior could be emulated thanks to this 
modularity. The problem with the scoring function was approached by acknowledging that 
no universal scoring function exists that performs well in all the biological systems of 
interest. For this reason, several scoring function were developed and tested, selecting the 
general CRScore function, based on GlideScore (Friesner, Banks et al. 2004), by default 
but allowing the user to select others with a simple flag.  
An improvement in pose prediction success is obtained as a result of the methodological 
changes. For rigid docking the program achieves a 91% (similar to the original CDOCK), 
but it obtains a reasonable 74% when flexibly modeled ligands are used instead. Far from 
perfect, this new version inherits some of the design faults of CDOCK and generates some 
new problems of its own. First, it uses the same approach to ligand flexibility than did 
CDOCK: a pre-generated ensemble of conformers. This design responds to the need of 
high speed in the calculations but reduces the internal sampling of the ligand. Besides, 
algorithms and near-linear runtimes routines for distributing the code over several 
processors are easier to implement. The main cost is that, as stated in the manuscript, this 
procedure is strongly dependent on the conformer generator and the quality of the models 
produced by the 1D-to-3D converter [this weakness is shared with all docking programs 
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(Friesner, Banks et al. 2004)], and, in many cases, near-native poses could not be located 
because of a defective ensemble of conformations. This explains some of the failures when 
results from flexible and rigid docking are compared. Another source of failure originates 
from the fact that other binding modes compatible with the electron distribution or 
electrostatic potential of the ligand are also possible when different conformations are used 
and the scoring function may fail to identify the one modeled by nature (Neves, Totrov et al. 
2012). 
Scoring function problems are solved partially by the new two-step scoring mechanism. 
The criteria in the sampling and final steps to select a proper solution are different. In the 
first step, we sample for possible poses, i.e. with a reasonable geometry, lack of clashes 
with the target and no feature mismatches. All of these are achieved through the use of the 
non-bonding terms of the Generalized AMBER force-field potential (Wang, Wolf et al. 
2004). Force field-based scoring functions have been recognized as very competent at 
selecting good poses but not very talented at selecting near-native poses due to its strict 
definition of the 12-6 van der Waals term (Friesner, Banks et al. 2004). For that reason, in 
the final step, all selected poses based on this first score are re-scored with a simplified 
hybrid potential, CRScore, that includes the scaled electrostatic and van der Waals terms 
plus hydrogen bonding and hydrophobic terms from ChemScore (Eldridge, Murray et al. 
1997).  
Desolvation is still an unsolved issue in docking programs despite the fact that most of 
them include some sort of algorithm to account for this molecular recognition event. The 
CDOCK scoring function adds desolvation energies by using the Implicit Solvent Model 
(Morreale, Gil-Redondo et al. 2007) developed by Morreale et al. ISM solved some 
problems that are common to other docking programs by accounting for the tendency to 
bury ligand charged groups inside the target. However, the penalties for mismatched polar 
groups were greatly underestimated. Attempts were made to add this ISM term to the 
CRScore function and use the PDBBind (Wang, Fang et al. 2004) set of X-ray structures 
with affinities measured for calibration and testing but the resulting potential tended to be 
overzealous regarding the desolvation costs. More work is underway to adapt other semi-
explicit scoring functions such as HYDE (Schneider, Lange et al. 2013) or ChemPLP (Korb, 
Stutzle et al. 2009) in order to improve the current CRScore-ISM scoring function. 
In the last work on classical CADD methods (article III) we introduced a method to 
compress the search space in docking experiments. First of all, we validated the 
performance of the CDOCK (Pérez and Ortiz 2001) program when using small molecules. 
Fragments, due to their size and nature, may not hold distinctive moieties such as 
hydrogen bond donors/acceptors or ionizable groups and this may cause problems when 
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the docking program and its scoring function attempt to find the most suitable pose 
(Sándor, Kiss et al. 2010). This is the main reason why they are described as more 
challenging for the current tools than the larger, more drug-like molecules that developers 
had originally in mind. In this case, the hard scoring function implemented in CDOCK 
appears to be an advantage to dock these small molecules since the minima are sharper. 
Bearing in mind that we seek to reduce the amount of time spent in VS protocols, we have 
compressed the chemical space by selecting a subset of small molecules or fragments that 
are present in ZINC (Irwin and Shoichet 2005)]. and available for purchase. Since the 
synthetic accessibility of the compounds in a drug-like chemical space may depend on the 
small pieces available to the chemists, we estimated that an ensemble of circa 2500 
molecules was reasonable to map this entire space. The main advantage of this method is 
that it avoids the clustering, and more importantly, the construction of an all-versus-all 
matrix needed for that process (Varin, Bureau et al. 2009) by using a stochastic algorithm 
that ensures the non-redundancy of the selected fragments. Comparing the results from a 
standard protocol to those obtained by using the compressed-expanded libraries presented 
here, we concluded that the number of ligands to dock was successfully reduced while 
preserving enough chemical diversity to achieve equivalent performance on a large variety 
of targets. However, we found some limitations in the process due to the nature of the 
ligands in our test sets. This is the case of Nuclear Hormone Receptors (NHR), whose 
typical ligands contain a steroid scaffold that was not available in our fragment set. This fact 
only highlights the need to prepare carefully a specific target-driven chemical library to 
achieve the best results.  
Setting aside the atomistic approach of the classical CADD employed in this thesis, two 
new global methods were developed to address the drug discovery problem from a 
different perspective. In the first work (article IV), we validated the use of ElectroShape 3D 
descriptors to construct polypharmocology networks and to predict side effects on the basis 
of information present in a pharmacology database such as DrugBank. We measured the 
amount of useful information of these networks and compared to the ones built from 
aligning targets binding sites. In addition, we used all this information to predict possible 
side effects based on the profiles of interacting targets. Finally we did a retrospective on-
target and off-target validation of the networks using several well known datasets such as 
the Directory of Useful decoys or the WOMBAT sets. Also, we have used a small set of 
non-included activities for the off-target prediction with considerable success. Regarding 
the side effects, mild results were obtained. Apparently, the tool is able to discard false side 
effects from the database; however, it has major problems to recognize most of the 
reported effects. It should be pointed out that many of these effects could not be related to 
only one target or the description is too vague to be correlated with a single source. As a 
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last contribution, we built a very simple web application that allows any user to perform 
unlimited queries against the DrugBank-based polypharmacology network. This tool 
predicts target profiles and side effects using ElectroShape 3D descriptors or the 2D 
Morgan fingerprints. It also represents the relationships between a selected target and their 
neighbors in the ligand and target spaces and shows the related compounds in the 
database with direct links to DrugBank. 
It is clear that there is room for improvement. The main limitation of this approach is that 
the predictions are entirely based on the knowledge available in the database. In this case 
we used DrugBank, which is a manually curated database. However, we found several 
problems due to the inclusion of very general and non-specific ligand-target pairs and the 
poor discrimination between cofactors, natural ligands and drugs for human use. Attempts 
to employ another database such as ChEMBL solved some of these issues but 
incorporated new problems of their own, derived from the cut-off of binding energy 
introduced to consider any compound as a true binder. Side effects are poorly predicted in 
this version, probably due to a limited compilation of target-side effects relationships and to 
the fact that more complex mechanisms than those reported here are responsible for these 
problems. The web application is very limited, and it only allows the representation of the 
first layer of neighbors of any target. This possibly undermines one of the most important 
uses of this network-based platform which is the investigation of hidden relationships. The 
results are also difficult to store and the interface is sometimes oversimplified. These 
problems may be addressed in future developments. 
In the penultimate piece of work, the AtlasCBS concept was materialized in the shape of a 
web tool that is able to describe the chemico-biological space in an effective manner. It 
uses the LEI framework and 2D planes to achieve such a description. Users can not only 
explore the contents of the most popular CBS databases but also upload their personal 
projects in a simple semicolon separated file or introduce the information manually via the 
web page. The display of hard-coded data from public sources together with the personal 
information provided becomes a powerful tool to analyze and compare projects and 
spaces. Registration is required for uploading a private dataset in order to ensure certain 
privacy to the users. The server implementation is based on open source technology such 
as the Chemistry Development kit (CDK), the Apache Tomcat application server or the 
JQuery framework and its plugins. The code developed is also open source and the server 
deployment could be achieved easily within minutes. Two mirrors currently exist, one in 
Madrid at the Centro de Biology Molecular Severo Ochoa and the other at the ChEMBL 
group at the European Bioinformatics Institute (EBI) in Cambridge. The latter is also linked 
to the Protein Data Bank (PDB) web interface. This allows any user to obtain direct 
information regarding a complex if it is available. In the PDB web interface there is also a 
170 
 
link for each complex to represent the CBS corresponding to a complex in the AtlasCBS 
server. 
As a web interface, the AtlasCBS has some technical limitations. In the first place, the 
speed and the number of compounds that can be loaded simultaneously strongly depend 
on the browser used by the user. As the application heavily relies on AJAX, JavaScript 
runtime engines become crucial. Secondly, data upload is also limited to one thousand 
compounds, which should be enough for most of the possible server uses. The AtlasCBS, 
despite its limitations, is a powerful tool that has been proved to provide excellent result 
analyzing past drug discovery projects and identifying optimal design paths. Future 
developments may solve the pending issues. 
Finally, in the last methodological piece of work, a de novo fragment-based design protocol 
has been implemented and tested using some successful cases available from the 
literature. We tested that the ligand efficiency framework is able to drive the optimization 
process. However, the nature of the protocol is still dependent on the user’s choices and 
decisions, which is not the ideal scenario.  
Unlike other parameters such as binding energy, ligand efficiency indices have not been 
analyzed for the optimal range of values in the optimization process, e.g. larger SEI 
(polarity) values may not be better than smaller ones, but different regions of the scale 
could be necessary for different targets. More work is needed in this regard to provide a 
comprehensive view of the scales and the range of values that could optimize the paths. 
Experimental validation is limited and was kindly provided by other groups. Two projects 
have provided the highest degree of evidence supporting the methods utility. The first one 
is the FtsZ VS project. In this case, docking, pharmacophore search and very detailed 
energy analysis were combined to produce a short list of 5 possible candidates that could 
bind to the intended target. Four out of five compounds were determined to bind to the FtsZ 
protein. 
The second one was the determination of the binding mode of substrates of a tannase 
enzyme from Lactobacillus plantarum, thanks to a collaboration with Dr. José Miguel 
Mancheño’s group at the Instituto de Química Física Rocasolano (CSIC, Madrid). The 
prediction of the binding mode was confirmed later when the X-ray structures of several 
complexes were determined by Qianming Chen et al. (Ren, Wu et al. 2013) 
Other modeling projects have employed the tools described in this thesis with success, but 
the results from these have not been experimentally tested or validated yet. 
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6. CONCLUSIONES 
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1. Se ha desarrollado una interfaz gráfica, métodos basados en ligandos y se ha 
actualizado la plataforma de cribado actual VSDMIP. 
 
2. Se han establecido diferentes protocolos para acortar los tiempos de cribado virtual 
y mejorar diversidad de los resultados. 
 
3. El desarrollo del programa de docking CRDOCK ha supuesto una mejora en la 
precisión y velocidad de los cribados virtuales.  
 
4. Se ha desarrollado la herramienta AtlasCBS que permite el análisis del espacio 
químico-biológico para optimización de compuestos. 
 
5. Se ha desarrollado una herramienta para la exploración de efectos adversos y 
perfiles de polifarmacología. 
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